dabigatran has been researched along with warfarin in 1116 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 36,573 | 2,143 | 14,728 |
| Protein | Taxonomy | dabigatran (IC50) | warfarin (IC50) |
|---|---|---|---|
| Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (1.79) | 29.6817 |
| 2010's | 883 (79.12) | 24.3611 |
| 2020's | 213 (19.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, T; Feng, Q; Guo, T; Jia, J; Li, X; Liu, Y; Pei, J; Song, Y; Wu, L; Wu, S; Zhang, Y; Zheng, X | 1 |
| Ma, Q | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Money, SR; Stone, WM; Tonnessen, BH | 1 |
| Ezekowitz, MD; Lionetti, DA; Nagarakanti, R; Nehmiz, G; Parcham-Azad, K; Pedersen, KE; Reilly, PA; Simmers, TA; Stangier, J; Wallentin, L | 1 |
| Francis, CW | 1 |
| Connolly, S; Ezekowitz, MD; Oldgren, J; Parekh, A; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Yusuf, S | 1 |
| Gage, BF | 2 |
| Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Liakishev, AA | 2 |
| Hankey, GJ | 2 |
| Baanstra, D; Eriksson, H; Goldhaber, SZ; Kakkar, AK; Kearon, C; Mismetti, P; Schellong, S; Schnee, J; Schulman, S | 1 |
| Vojácek, J | 1 |
| Spinler, SA | 1 |
| Ansell, J; Zikria, J | 1 |
| Houston, DS; Zarychanski, R | 1 |
| Conard, J; Horellou, MH; Samama, MM | 1 |
| Tomoda, H | 1 |
| Gattellari, M; Worthington, JM | 1 |
| Mannucci, PM; Moia, M | 1 |
| Barry, M | 1 |
| Ibrahim, S; Jespersen, J; Poller, L | 2 |
| Khoo, CW; Lip, GY | 1 |
| Okumura, K | 1 |
| Lackner, KJ; Peetz, D | 1 |
| Teachey, DT | 1 |
| Prandoni, P; Taher, A | 1 |
| Banda, ZK; Benmira, S; Bhattacharya, V | 1 |
| Malaga, G; Malasquez, G; Salazar, CA | 1 |
| Albers, GW; Schwartz, NE | 1 |
| Díaz-Cremades, JM; Fernández-Fuertes, F; Ruano, JA | 1 |
| Lane, DA; Lip, GY | 2 |
| Panchenko, EP | 2 |
| Alings, M; Connolly, SJ; Dans, A; Eikelboom, J; Ezekowitz, MD; Flather, M; Franzosi, MG; Oldgren, J; Pais, P; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Jamil-Copley, S; Kanagaratnam, P | 1 |
| Lam, YY; Ma, TK; Yan, BP | 1 |
| Broukhim, M; Halperin, JL | 1 |
| Edwards, D | 1 |
| Hughes, B | 1 |
| Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Michota, F | 1 |
| Connolly, SJ; Di Pasquale, G; Diener, HC; Ezekowitz, MD; Reilly, PA; Wallentin, L; Xavier, D; Yang, S; Yusuf, S | 1 |
| Heidbuchel, H; Verhamme, P | 1 |
| Neilson, RF | 1 |
| Oliver, M | 1 |
| Aikens, TH; Chernick, MR; Connolly, SJ; Ezekowitz, MD; Lip, GY; Parekh, A; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S | 1 |
| Ansell, J | 1 |
| DeDea, L | 1 |
| Connolly, SJ | 1 |
| You, JH | 1 |
| Kirsch, B | 1 |
| Bradley-Kennedy, C; Connolly, S; Kansal, AR; Linnehan, J; Peng, S; Plumb, JM; Sorensen, SV | 1 |
| Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Eikelboom, JW; Haroun, MJ; Paikin, JS | 1 |
| Uchiyama, S | 2 |
| Beasley, BN; Temple, R; Unger, EF | 1 |
| Edwards, DB; Silverberg, J | 1 |
| Berg, AM | 1 |
| Cannon, CP; Stecker, EC | 1 |
| Fisher, WD | 1 |
| Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Gage, BF; Shah, SV | 1 |
| Arnaout, S; Musallam, KM; Rabah, A; Sawaya, FJ; Sawaya, J | 1 |
| Batjer, HH; Bendok, BR; Bernstein, R; Rahme, RJ | 1 |
| Lee, TH | 1 |
| Eid, TJ; Shah, SA | 1 |
| Encinas, J; Ikegami, K; Ohmura, T; Takahashi, I | 1 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Ganjehei, L; Massumi, A; Rasekh, A; Razavi, M | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Belavic, JM | 1 |
| Mega, JL | 1 |
| Averkov, OV | 1 |
| Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Cianchetti, FA; Foerch, C; Lauer, A; Lo, EH; Pfeilschifter, W; Schaffer, CB; Schlunk, F; Schulz, E; Steinmetz, H; Van Cott, EM | 1 |
| Hunchuck, JE; Lake, JD | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 2 |
| Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
| Bartholomew, JR; Wartak, SA | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 2 |
| Jolobe, OM | 2 |
| Yates, SW | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Beyth, RJ; Landefeld, CS | 1 |
| Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR | 1 |
| Diener, HC; Hohnloser, SH; Lip, GY; Weber, R | 1 |
| Deloughery, TG; Liem, TK | 1 |
| Büller, HR; Combe, S | 1 |
| Asakura, H | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Kamal, AK; Khan, M; Raza, E | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, J; Ezekowitz, M; Hohnloser, SH; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Freuler, M; Pezzotti, W | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Diener, HC; Eikelboom, J; Granger, CB; Hacke, W | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Knight, BP | 1 |
| Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR | 1 |
| Easton, JD; Johnston, SC; Kamel, H; Kim, AS | 1 |
| Abraham, ME; Marcy, TR | 1 |
| Alpert, JS | 1 |
| Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM | 1 |
| Abdelhafiz, AH; Ali, A; Bailey, C | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Iyer, V; Reiffel, JA; Singh, HS | 1 |
| Bergholdt Asmussen, M; Langkilde, LK; Overgaard, M | 1 |
| Eeckhoudt, S; Hermans, C; Lambert, C | 1 |
| DiNicolantonio, JJ | 1 |
| Bryer, A | 1 |
| Baumgarten, P; Bohmann, F; Foerch, C; Lindhoff-Last, E; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Baker, RI; Harper, P; McLintock, C | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL | 1 |
| Bommer, WJ | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Schulman, S | 3 |
| Vanerio, G; Vidal, A | 1 |
| Firriolo, FJ; Hupp, WS | 1 |
| Das, P; Jha, SK; Kabra, R; Koshy, SK; Shaheen, MH | 1 |
| Ismael, AG; Ribowsky, JH | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Hori, M | 1 |
| Freeman, MK; Hughes, PJ | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Garcia, DA; Granger, CB | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, JW; Friedman, J; Granger, CB; Harper, R; Härtter, S; Kappetein, AP; Lehr, T; Mack, MJ; Noack, H; Van de Werf, F | 1 |
| Bhatt, DL; Kar, S | 1 |
| Ataullakhanov, FI; Panteleev, MA; Sinauridze, EI | 1 |
| Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J | 1 |
| McKeage, K | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Ansell, J; Mantha, S | 1 |
| Cheng, G; Tsui, KK; Wong, RS; You, JH | 1 |
| Radecki, RP | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Reed, SD | 1 |
| Arnold, DM; Crowther, MA; Eltringham-Smith, LJ; Gataiance, S; Lambourne, MD; Sheffield, WP | 1 |
| Bilen, O; Teruya, J | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Mangiafico, M; Mangiafico, RA | 1 |
| Huang, C; Shin, J; Siu, M; Vu, L; Wong, S | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Zhang, S | 1 |
| Al-Sallami, HS; Duffull, SB; Faed, JM; Wright, DF; Zufferey, PJ | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K | 1 |
| Griffiths, M; Scully, C | 1 |
| Taylor, J | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Nguyen, T; Wong, E | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Kopecky, S | 1 |
| Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS | 1 |
| Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
| Brenner, B; Hoffman, R | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Cheema, AA; Jones, P; Konduru, SV; Li, Y; Ramza, B; Wimmer, AP | 1 |
| Ellis, CR; Nagarakanti, R | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Aalbers, J | 1 |
| Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM | 2 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| García Alegría, J | 1 |
| Ruiz-Giménez Arrieta, N | 1 |
| Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| De Caterina, R; Renda, G | 1 |
| Harvey, P | 1 |
| Okada, Y; Yasaka, M | 2 |
| Wooten, JM | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Gross, PL; Weitz, JI | 1 |
| Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M | 1 |
| Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E | 1 |
| Brueckmann, M; Connolly, SJ; Dans, AL; Eikelboom, JW; Ezekowitz, M; Nakamya, J; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Sinnaeve, PR; Van de Werf, F | 1 |
| Kanorsky, SG; Shevelev, VI | 2 |
| Deitelzweig, SB | 1 |
| Greenspon, AJ | 1 |
| Ikitimur, B; Karadağ, B; Öngen, Z | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S | 1 |
| Connors, JM | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Devlin, HL; Hosman, AE; Shovlin, CL | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Galanis, T; Merli, GJ | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Dolgin, E | 1 |
| Reichman, ME; Southworth, MR; Unger, EF | 1 |
| Camarero, MO; Castaño, MP; Milla, SL; Piñero-Saavedra, M | 1 |
| Berger, R; Chase, M; Ganetsky, M; Salhanick, SD | 1 |
| Lim, SL; Maxwell, E | 1 |
| Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Abi-Saleh, B; Alam, S; Baranowski, B; Bassiouny, M; Borek, PP; Callahan, T; Chung, M; Diab, M; Dresing, T; Hussein, A; Kanj, M; Khoury, M; Lindsay, BD; Martin, DO; Niebauer, M; Rickard, J; Saliba, W; Sengupta, J; Sey, A; Shao, M; Tchou, PJ; Varma, N; Wazni, O | 1 |
| Callréus, T; Due, KM; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T | 1 |
| Attia, JR; Pearce, R | 1 |
| Eikelboom, JW; Hankey, GJ | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Chevalier, J; de Pouvourville, G; Giroud, M | 1 |
| Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
| Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP | 1 |
| Yasaka, M | 1 |
| Avila, C; Gullett, D; Johnson, ES; Kokaram, CR; Parra, MW; Wichner, ZA; Zucker, L | 1 |
| Kalus, JS | 1 |
| Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G | 1 |
| Pelargonio, G; Perna, F | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Kerr, R; Ogden, G; Sime, G | 1 |
| Connolly, SJ; Korhonen, M; Monz, BU; Noack, H; Pooley, J | 1 |
| Bett, N; Hamilton-Craig, C; Luis, C; Luis, SA; Poon, K; Shukla, A | 1 |
| Micieli, A; Singh, SM; Wijeysundera, HC | 1 |
| Heidenreich, PA | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Bauer, KA | 1 |
| Klein, HH | 1 |
| Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E | 1 |
| Chen, JH; Connolly, SJ; Dans, AL; Ezekowitz, MD; Hori, M; Kim, SS; Koyanagi, M; Lau, CP; Liu, LS; Omar, R; Pais, P; Reilly, PA; Tan, RS; Tanomsup, S; Wallentin, L; Watanabe, M; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Pollack, CV | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Finsterer, J; Stöllberger, C | 1 |
| Diener, HC | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Rider, EB; Rider, OJ | 1 |
| Bhimani, AA; Hong, M | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Bamimore, A; Mounsey, JP | 1 |
| Djalali, S | 1 |
| Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R | 1 |
| Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T | 1 |
| Dalen, JE | 1 |
| DeRemer, CE; Elewa, HF; Gujral, J; Joshua, TV; Keller, K | 1 |
| Bell, S; Dawes, M; Nand, J | 1 |
| Fanikos, J | 1 |
| Dinkel, J; Foerch, C; Gupta, R; Hayakawa, K; Karatas, H; Lauer, A; Leung, W; Lo, EH; Schlunk, F; Steinmetz, H; Won, SY | 1 |
| Davis, C; Lee, M; Robertson, C; Shivakumar, S | 1 |
| Alvrtsyan, H; Francis, K; Matchar, D; Miyasato, G; Rao, Y; Sanchez, H; Sander, S; Siu, K; Walker, D; Yu, C; Zalesak, M | 1 |
| Avorn, J | 1 |
| Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C | 1 |
| Ansell, J; Shameem, R | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Camm, AJ; Hohnloser, SH | 1 |
| Bahmaid, RA; Bin Abdulhak, AA; Garbati, MA; Khan, AR; Sanders, SU; Spertus, JA; Steigerwalt, KE; Tleyjeh, IM; Wimmer, AP | 1 |
| Lip, GY; Van Gelder, IC; Van Veldhuisen, DJ | 1 |
| Doraiswamy, VA; Gesheff, MG; Gurbel, PA; Slepian, MJ; Tantry, US | 1 |
| Rosenfeld, JV; Schaerf, NB; Thomas, PA | 1 |
| Hylek, EM | 2 |
| Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU | 1 |
| Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M | 1 |
| Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H | 1 |
| Brueckmann, M; Connolly, S; Eikelboom, J; Ezekowitz, M; Le Heuzey, JY; Marijon, E; Pogue, J; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Azuma, S; Lum, CJ | 1 |
| Holmes, D | 1 |
| Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S | 1 |
| Paré, G; Ross, S | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Chandler, WL | 1 |
| Bin Abdulhak, AA; Khan, AR; Tleyjeh, IM; Wimmer, AP | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Clemens, A; Fraessdorf, M; Friedman, J | 1 |
| Waks, JW; Zimetbaum, PJ | 1 |
| Cove, CL; Hylek, EM | 1 |
| Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Celik, S; Sipahi, I; Tozun, N | 1 |
| Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Omote, Y; Yamashita, T; Yunoki, T | 1 |
| Manning, JA | 1 |
| Kitazono, T | 1 |
| Laffan, M; Shapiro, S | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S | 1 |
| Albenque, JP; Boveda, S; Marijon, E; Providência, R | 1 |
| Bounameaux, H; Verhamme, P | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Bartels, DB; Clemens, A; Gawlik, M; Schnee, J; Schneider, G; Schoof, N; Zint, K | 1 |
| Chintala, M; Keohane, C; Li, Q; Ni, W; O'Neill, K; Shang, J; Wang, M; Wei, H | 1 |
| Erickson, SC; Harada, AS; Lew, HC; Solow, BK; Tsai, K; Yang, J | 1 |
| Bajorek, B; Wang, Y | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Chang, CH; Chen, JH; Lin, LJ; Yang, YH | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C | 1 |
| Cordova, EG; del Aguila, D; Salazar, CA | 1 |
| Amorosi, SL; Armstrong, S; Da Deppo, L; Garfield, S; Stein, K | 1 |
| Iung, B; Vahanian, A | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brannath, W; Schmidt, S | 1 |
| Brieger, D | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Birnie, DH; Essebag, V; Healey, JS | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Breik, O; Cheng, A; Goss, A; Sambrook, P | 1 |
| Hess, T; Konturek, P | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Kihara, Y; Nakano, Y; Sairaku, A | 1 |
| AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS | 1 |
| Cohen, MR; Mattison, DR; Moore, TJ | 1 |
| Amirehsani, KA; Scott, KA | 1 |
| McCormick, NJ; Meechan, JG; Moore, UJ; Norouzi, M | 1 |
| Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Donovan, JL; Kanaan, AO; Rollins, BM; Silva, MA | 1 |
| Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Aslan, O; Ozdemir, M; Senol, H; Ugur-Yildiz, M; Yaylali, YT; Yildirim, S; Yurtdas, M | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Hernández Olmedo, M; Suárez Fernández, C | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Connolly, SJ; Wallentin, L; Yusuf, S | 1 |
| Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Ammollo, CT; Colucci, M; Semeraro, N; Testa, S; Visino, F; Zaccaria, F | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Kovács, T | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Dzeshka, MS; Lip, GY | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Hassager, C; Kjaergaard, J; Saust, LT; Thomsen, JH; Wachtell, K | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Redberg, RF | 1 |
| Baik, SH; Hernandez, I; Piñera, A; Zhang, Y | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 1 |
| Eikelboom, JW; Hart, RG | 1 |
| Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY | 1 |
| Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
| Brueckmann, M; Connolly, SJ; Douketis, JD; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Healey, JS; Noack, H; Oldgren, J; Reilly, P; Spyropoulos, AC; Wallentin, L | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Belikov, LN; Savchuk, OF; Sukovatykh, BS; Sukovatykh, MB | 1 |
| Amin, A; Deitelzweig, S | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Einecke, D | 1 |
| Cantürk, E; Güler, E; Karaca, O; Kızılırmak, F; Omaygenç, O | 1 |
| Marcus, H; Nandi, D; Tai, D; Vakharia, NN; Vakharia, VN | 1 |
| Berengo, M; Brunello, G; De Biagi, M; Pengo, V; Sivolella, S | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Bultas, J | 1 |
| Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M | 1 |
| Cantillon, D; Coleman, CM; Kanj, M; Khalaf, S; Mould, S; Saliba, W; Wazni, O | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Loffredo, L; Perri, L; Violi, F | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AK; Kearon, C; Kreuzer, J; Schellong, S; Schulman, S | 1 |
| Oberhofer, E | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Hitos, K; Kumar, N; Phan, K; Pison, L; Thomas, SP; Wang, N | 2 |
| Castiblanco, SA; Garg, J; Jacobs, LE; Palaniswamy, C; Zak, M | 1 |
| Bertran, EA; Forman, MJ; Hoffman, JL; Koerber, JM; Priziola, JL; Smythe, MA | 1 |
| Harenberg, J; Krejczy, M; Lip, GY; Obermann, K; Wehling, M | 1 |
| Brookhart, MA; Fang, G; Farley, JF; Gehi, AK; Lauffenburger, JC; Rhoney, DH | 1 |
| Husein, H; Samo, S; Sherid, M; Sifuentes, H; Spurr, C; Sridhar, S; Sulaiman, S; Tupper, R | 1 |
| Abe, J; Kato, Y; Kinosada, Y; Nagasawa, H; Nakamura, M; Nakayama, Y; Suzuki, T; Suzuki, Y; Ueda, N; Umetsu, R | 1 |
| Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH | 1 |
| Mracsko, E; Na, SY; van Ryn, J; Veltkamp, R | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Hao, L; Rong, B; Wang, JT; Xie, F; Yue, X; Zhang, W; Zhang, Y; Zheng, ZT; Zhong, JQ; Zhu, Q | 1 |
| Narasimha Krishna, V; Rizk, DV; Saxena, N; Warnock, DG | 1 |
| Gehrie, E; Tormey, C | 1 |
| Amato, A; Dentali, F; Dumonceau, JM; Paggi, S; Radaelli, F; Repici, A; Rondonotti, E | 1 |
| Aisha, B; Eng, DT; Hashim, MI; Hussin, A; Kaur, S; Koh, KW; Muhammad, Z; Omar, R; Rebo, R; Rusani, BI; Shanmugam, R; Sivalingam, L; Umadevan, D; Yap, LB | 1 |
| Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N | 1 |
| Bonde, AN; Fosbøl, EL; Gislason, GH; Hansen, ML; Lamberts, M; Lip, GY; Olesen, JB; Staerk, L; Torp-Pedersen, C | 1 |
| Alenholt, A; Engdahl, J; Fodor, E; Frick, M; Hagwall, K; Johansson, AK; Juhlin, T; Lind, S; Paul Nordin, A; Rorsman, C; Rosenqvist, M | 1 |
| Böhm, M; Brueckmann, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Kratz, MT; Reilly, PA; Schirmer, SH; Schumacher, H; Wallentin, L; Yusuf, S | 1 |
| Singh, SM; Wijeysundera, HC | 1 |
| Kim, BW; Kim, JS | 1 |
| Brambatti, M; Brueckmann, M; Clemens, A; Connolly, SJ; Darius, H; Ezekowitz, MD; Healey, JS; Noack, HH; Oldgren, J; Wallentin, L; Yusuf, S | 1 |
| Agewall, S; Huber, K; Lip, GY; Rubboli, A | 1 |
| Brookhart, MA; Ellis, AR; Girman, CJ; Jonsson Funk, M; Simpson, RJ; Stürmer, T; Wyss, R | 1 |
| Butera, JN; Connell, NT | 1 |
| Alexander, GC; Barnes, GD; Goldberger, ZD; Lucas, E | 1 |
| Ganetsky, M | 1 |
| Ageno, W; Riva, N | 1 |
| Marietta, M | 1 |
| Alla, F; Billionnet, C; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Bolton-Maggs, PH; Shearer, MJ; Thachil, J; Walsh, V | 1 |
| Alonso-Coello, P; Brosa, M; Carles, M; Garcia-Alamino, JM; Guyatt, G; Souto, JC | 1 |
| Goette, A; Hammwöhner, M | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Aghi, A; Arcidiacono, MV; Dalle Carbonare, L; Dusso, A; Fusaro, M; Gallieni, M; Pasho, S; Valenti, MT | 1 |
| Connolly, SJ; Ezekowitz, MD; Fukaya, T; Hori, M; Kleine, E; Reilly, PA | 1 |
| Jugrin, AV; Lamotte, M; Sunderland, T; Urbich, M; Ustyugova, A | 1 |
| Aytekin, S; Baltaci, D; Basar, C; Ekinozu, I; Kaya, E; Turker, Y | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Ezekowitz, MD; Nagarakanti, R; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Chan, NC; Fredenburgh, JC; Jaffer, IH; Stafford, AR; Weitz, JI; Whitlock, RP | 1 |
| Kusano, K; Miyamoto, K; Nakasuka, K | 1 |
| Schlimpert, V | 1 |
| Avgil-Tsadok, M; Behlouli, H; Eisenberg, MJ; Essebag, V; Jackevicius, CA; Pilote, L; Rahme, E | 1 |
| Alvrtsyan, H; Francis, K; Ghosh, S; Matchar, D; Rao, Y; Sanchez, H; Sander, S; Yu, C | 1 |
| Ang, ES; De Silva, DA; Fabiaña, N; Ramaswami, AP | 1 |
| Demir, S; Kendirli, MT; Ozdag, MF; Togrol, RE | 1 |
| Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D | 1 |
| De Francesco, M; Hösel, V; Jugrin, AV; Lamotte, M; Sunderland, T; Ustyugova, A | 1 |
| Chan, EW; Chan, PH; Chiang, CE; Hai, JJ; Huang, D; Lau, CP; Li, WH; Siu, CW; Tse, HF; Wong, IC; Yin, LX; Zhu, J | 1 |
| Eriksson, H; Feuring, M; Friedman, J; Goldhaber, SZ; Hantel, S; Kakkar, A; Kearon, C; Kreuzer, J; Majeed, A; Schellong, S; Schulman, S | 1 |
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Mizuno, S; Nagamine, Y; Sano, H; Tanahashi, N | 1 |
| Collins, J; Fraeman, K; Reynolds, MW; Schnee, J; Schwartzman, E; Siu, K; Villines, TC | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD; Zint, K | 1 |
| Shaw, P; Wood, M | 1 |
| Condliffe, R; Elliot, CA; Hurdman, J; Kiely, DG; Maclean, RM; Quadery, R; Sabroe, I; van Veen, JJ | 1 |
| Grotts, J; Kaminski, S; Pozzessere, A | 1 |
| Ackery, A; Sholzberg, M; Wood, B | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Cairns, JA; Ciaccia, A; Fisher, WD; Kong, C; Semchuk, W; Turpie, AG; Weitz, JI | 1 |
| Anderson, E; Dyke, C; Glogoza, M; Johnke, K; Leedahl, D; Newman, R | 1 |
| Gorbunova, EV; Mamchur, SE; Romanova, MP; Sherbinina, DA | 1 |
| Di Minno, A; Di Minno, G; Spadarella, E; Spadarella, G; Tremoli, E | 1 |
| Avgil Tsadok, M; Humphries, KH; Jackevicius, CA; Pilote, L; Rahme, E | 1 |
| Gislason, GH; Hansen, ML; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Schjerning, AM; Staerk, L; Torp-Pedersen, C | 1 |
| Fonseca, E; Ghosh, S; Hess, GP; Sander, SD | 1 |
| Barnes, GD; Froehlich, JB; Hutton, DW; Levine, DA; Salata, BM | 1 |
| Connolly, S; Eikelboom, J; Ezekowitz, M; Joseph, P; Oldgren, J; Pare, G; Reilly, P; Siegbahn, A; Themeles, E; Wallentin, L; Wang, J; Yusuf, S | 1 |
| Potpara, TS | 1 |
| Gnjidic, D; Hanger, HC; Hilmer, SN; Jamieson, HA; Kaluarachchi, C; Nishtala, PS | 1 |
| Gagne, JJ; Glynn, RJ; Schneeweiss, S; Wangge, G | 1 |
| Forslund, T; Hjemdahl, P; Wettermark, B | 1 |
| Borges, M; Caldeira, D; Costa, J; Fiorentino, F; Gouveia, M; Inês, M; Lopes Pereira, C; Pinheiro, L; Vaz-Carneiro, A | 1 |
| Barake, W; Baranchuk, A; Chu, K; Lamb, T; Lamba, J; Marr, JN; McIntyre, WF; Mohajer, K; Oqab, Z; Quadros, K; Quinn, KL; van Oosten, E; Yazdan-Ashoori, P | 1 |
| Bruno, A; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Tate, N; Trocio, J | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Noguez, JH; Ritchie, JC | 1 |
| Andersson, U; Aulin, J; Connolly, SJ; Ezekowitz, MD; Hijazi, Z; Huber, K; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L | 1 |
| Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Aonuma, K; Goya, M; Hirao, K; Nogami, A | 1 |
| Hussein, A; Saliba, W; Wazni, OM | 1 |
| How, CH | 1 |
| Didier, R; Escarcega, RO; Kiramijyan, S; Koifman, E; Lipinski, MJ; Torguson, R; Waksman, R | 1 |
| Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC | 1 |
| Andrade, JG; Ciaccia, A; Connors, S; Krahn, AD; Purdham, D; Skanes, AC | 1 |
| Shao, XH; Wan, HB; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Dolginsky, M; Kym, E; Nolting, L; Orrico, KB; Romanelli, RJ | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Bancroft, T; Lim, J; Sander, SD; Swindle, JP; Wang, C | 1 |
| Dagres, N; Hindricks, G; Jokic, V; Lane, DA; Larsen, TB; Lip, GY; Potpara, TS | 1 |
| Alamneh, EA; Bereznicki, LR; Chalmers, L | 1 |
| Anand, S; Chan, EW; He, Y; Leung, WK; Li, X; Siu, CW; Wong, IC | 1 |
| Albuquerque, FP; Aras, R; de Almeida Nunes, B; de Bulhões, FV; de Souza Fernandes, AM; de Souza Roriz, P; Durães, AR | 1 |
| Brueckmann, M; Connolly, S; Eikelboom, JW; Feuring, M; Hwang, HG; Majeed, A; Noack, H; Schulman, S; Wallentin, L; Yusuf, S | 1 |
| Gomes, T; Juurlink, DN; Laupacis, A; Mamdani, MM; Sholzberg, M; Yao, Z | 1 |
| Brueckmann, M; Connolly, SJ; Douketis, JD; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Healey, JS; Oldgren, J; Reilly, P; Spyropoulos, AC; Wallentin, L; Yusuf, S | 1 |
| Ayala-Paredes, F; Birnie, DH; Coutu, B; Coyle, D; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Nery, P; Philippon, F; Sandhu, RK; Sapp, J; Verma, A; Wells, G | 1 |
| Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M | 1 |
| Ferreira, J; Silva Miguel, L | 1 |
| Åsberg, S; Hijazi, Z; Norrving, B; Oldgren, J; Terent, A | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kent, AP; Noack, H; Oldgren, J; Pogue, J; Reilly, PA; Spahr, J; Wallentin, L; Yusuf, S | 1 |
| Aizawa, Y; Fukuda, K; Fukumoto, K; Igarashi, A; Ikeda, S; Kashimura, S; Katsumata, Y; Kimura, T; Kunitomi, A; Nakajima, K; Nishiyama, N; Nishiyama, T; Takatsuki, S; Tanimoto, Y | 1 |
| Blum, RA; Lindfield, D | 1 |
| Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C | 1 |
| Gauthier-Lewis, ML; Riley, TR; Riley, TT; Sanchez, CK | 1 |
| Aita, A; Angeli, F; Bartolini, C; Reboldi, G; Verdecchia, P | 1 |
| Garg, AX; Gomes, T; Harel, Z; Juurlink, DN; Mamdani, M; Wald, R; Yao, Z | 1 |
| Masuda, Y; Matsuno, K; Shimizu, C | 1 |
| Baik, SH; Hernandez, I; Zhang, Y | 1 |
| Komaroff, AL | 1 |
| Baker, D; Narasimhan, S; Wilsmore, B | 1 |
| Majeed, A; Schulman, S; Shrum, J | 1 |
| Harenberg, J | 1 |
| Aksoy, H; Ata, N; Ayturk, M; Dal, K; Ozkan, S; Ozturk, M; Şabanoglu, C; Tanalp, AC; Topaloglu, C; Yavuz, B; Yavuz, BB | 1 |
| Hayes, CJ; Martin, BC; Shah, A; Shewale, A | 1 |
| Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Feuring, M; van Ryn, J | 1 |
| Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
| Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R | 1 |
| Aronow, WS; Chatterjee, S; Kundu, A; Owan, T; Ryan, JJ; Sardar, P | 1 |
| Lesko, LJ | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Eddings, W; Franklin, JM; Gagne, JJ; Glynn, RJ; Schneeweiss, S; Wang, SV | 1 |
| Bjerregaard Larsen, T; Gorst-Rasmussen, A; Lip, GY | 1 |
| Bair, TL; Bunch, TJ; Crandall, BG; Cutler, MJ; Day, JD; Jacobs, V; Mallender, C; May, HT; Osborn, JS; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Hart, C; Schmid, S | 1 |
| Boey, JP; Gallus, A | 1 |
| Cappato, R; De Caterina, R; Ezekowitz, MD; Giugliano, RP; Patel, MR; Piccini, JP; Renda, G; Ricci, F; Zimarino, M | 1 |
| Abe, H; Aizawa, Y; Fujii, Y; Jimbo, Y; Sato, M; Takahashi, H; Takano, H | 1 |
| Battat, E; Bitterman, H; Dotan, SG; Eikelboom, JW; Ellis, MH; Ginsberg, JS; Hammerman, A; Hirsh, J; Neuman, T | 1 |
| Al-Ahmad, A; Barnes, GD; Freeman, JV; Garber, AM; Go, AS; Heidenreich, PA; Hlatky, MA; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
| Coleman, CI; Evers, T; Tangirala, M | 1 |
| Mizoguchi, T; Yasaka, M | 1 |
| Kuwashiro, T; Okada, Y; Sahara, N | 1 |
| Abraham, NS; Asirvatham, SJ; Bellolio, MF; Del-Carpio Munoz, F; Gersh, BJ; McBane, RD; Noseworthy, PA; Rabinstein, AA; Shah, ND; Yao, X | 1 |
| Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Ageno, W; Eikelboom, J; Lip, GY | 1 |
| Braun, D; Feinstein, DL; Givogri, MI; Kalinin, S; Marangoni, MN; Moyano, AL; Polak, P; Situ, A | 1 |
| Fukuoka, H; Hoshida, S; Ikeoka, K; Inui, H; Kanda, T; Shinoda, Y; Sunaga, A; Uematsu, M; Watanabe, T | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schulman, S | 1 |
| Abraham, NS; Bellolio, MF; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Chien, KL; Hu, MM; Lin, SY; Lin, ZF; Su, CL; Wang, J; Wu, FL | 1 |
| Bhattacharya, B; Davis, KA; Maung, AA; Schuster, KM | 1 |
| Colquhoun, D; Freedman, SB; Ortiz, M; Simons, LA; Thomas, G; Waterhouse, BJ | 1 |
| Clemens, A; Hösel, V; Klok, FA; Konstantinides, SV; Lankeit, M; Schulman, S; Tilke, C; Yollo, WD | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Ezekowitz, MD; Jacobs, M; Litherland, C; Nagarakanti, R; Noack, H; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Hamilton, M; Horblyuk, R; Kamble, S; Keshishian, A; Lip, GY; Mardekian, J; Pan, X | 1 |
| Berger, K; Lesch, CA; Sin, JH | 1 |
| Bruno, A; Kamble, S; Kawabata, H; Lip, GY; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F | 1 |
| Bhatt, DL; Blatchford, J; Brueckmann, M; Cannon, CP; Ellis, SG; Ferreiros Ripoll, E; Gropper, S; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GY; Manassie, J; Massaro, JM; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Kawasugi, K; Kita, H; Kuyama, Y; Shirai, T; Yamamoto, T | 1 |
| Eikelboom, J; Merli, G | 2 |
| Musgrave, KM; Powell, J | 1 |
| Buck, J; Cram, P; Gage, BF; Kaboli, P; Vaughan Sarrazin, MS | 1 |
| Davies, RA; Orr, Y; Perera, NK | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Steed, MB; Swanson, MT | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Henry, BL; Kumar, R; Rahman, AM | 1 |
| Falck, P; Fride Tvete, I; Ghanima, W; Halvorsen, S; Hoxmark, C; Jonasson, C; Solli, O | 1 |
| Torjesen, I | 1 |
| Bajorek, BV; Pandya, E | 1 |
| Bhave, A; Dalal, JJ; Dhall, A | 1 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 1 |
| Aisenberg, J; Brueckmann, M; Chatterjee, P; Connolly, S; Desai, J; Ezekowitz, M; Flack, KF; Ilgenfritz, J; Kolb, JM; Reilly, P; Wallentin, LC; Yusuf, S | 1 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| Butala, NM; Kartoun, U; Kennedy, KF; Mahmood, S; Secemsky, EA; Shaw, SY; Wasfy, JH; Yeh, RW | 1 |
| Assar, MD; Ball, T; Cox, KM; McCullough, PA | 1 |
| Keskar, V; Sood, MM | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Alonso, A; Bengtson, LGS; Chen, LY; Lutsey, PL; MacLehose, RF | 2 |
| Chan, EW; Chan, PH; Chiang, CE; Huang, D; Lau, CP; Li, WH; Lip, GYH; Siu, CW; Tse, HF; Wong, ICK | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD | 1 |
| Dai, Y; Gao, X; Tan, HQ; Yang, YM; Zhu, J | 1 |
| Armstrong, D; Koea, JB; Nimmo, M | 1 |
| Brooks, MM; Chin, PK; Hernandez, I; Saba, S; Zhang, Y | 1 |
| Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y | 1 |
| Kawada, T | 2 |
| Balla, S; Flaker, G; Koerber, S | 1 |
| Chen, HC; Liu, CY | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Antoniak, S; Bastarache, JA; Beck, MA; Gondouin, B; Mackman, N; Mickelson, J; Monroe, DM; Neidich, SD; Subramaniam, S; Tatsumi, K | 1 |
| Etminan, M; Guo, M; Talany, G | 1 |
| Boos, CJ; Brown, LAE | 1 |
| Ali, JT; Ali, S; Aydelotte, JD; Brown, CV; Coopwood, TB; Daley, MJ; Enright, Z; Nguyen, J; Teixeira, PG; Vadiei, N | 1 |
| Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M | 1 |
| Bhatt, DL; Vaduganathan, M | 1 |
| Ayyagari, P; Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Al-Rawi, S; Alhaddad, A; Elewa, H; Mahmoud, H; Nounou, A; Singh, R | 1 |
| Darius, H | 1 |
| Bowrin, K; Briere, JB; Roberts, J; Tatarsky, B; Wood, R | 1 |
| Lip, GY; Potpara, TS | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AJ; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Bai, Y; Deng, H; Lip, GY; Shantsila, A | 1 |
| Dowlatshahi, D; Frymire, E; Giulivi, A; Gomes, T; Holbrook, AM; Johnson, AP; Khuu, W; Mamdani, M; Schulman, S; Shepherd, LE; Simpson, CS; Wells, PS; Xu, Y | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Cangemi, DJ; Cipher, DJ; Feagins, LA; Krill, T; Spechler, SJ; Weideman, R | 1 |
| Franca, LR; Haertter, S; Huang, F | 1 |
| Antoniou, T; Juurlink, D; Mamdani, M | 1 |
| Kolegova, II; Koziolova, NA; Polyanskaya, EA | 1 |
| Fujisaki, J; Hirasawa, T; Horiuchi, Y; Igarashi, M; Ishiyama, A; Iwasaki, R; Michitaka, K; Mita, E; Ninomiya, T; Omae, M; Tomida, H; Tsuchida, T; Yamada, T; Yamamoto, Y; Yoshio, T | 1 |
| Clarkesmith, DE; Lane, DA; Lip, GYH | 1 |
| Biss, B; Brouwer, MA; Calkins, H; Gerstenfeld, EP; Grimaldi, M; Guiver, K; Hohnloser, SH; Nordaby, M; Okumura, K; Schilling, R; Serota, H; Verma, A; Willems, S | 1 |
| Chan, EW; Cheung, CL; Lam, JK; Lau, WC; Lee, AC; Lip, GY; Man, KK; Sing, CW; Siu, CW; Wong, IC | 1 |
| Birnie, DH; Connolly, SJ; Coutu, B; Douketis, J; Essebag, V; Ezekowitz, M; Healey, JS; Hohnloser, SH; Lip, GYH; Moriarty, A; Oldgren, J; Parkash, R; Proietti, R; Wang, J | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Ummarino, D | 1 |
| Adachi, T; Fujioka, S; Hoshino, H; Takagi, M | 1 |
| Burr, N; Corp, A; Kane, JS; Lummis, K; Sood, R; Subramanian, V | 1 |
| Bhave, PD; Chrischilles, E; Girotra, S; Giudici, M; Hodgson-Zingman, D; Mazur, A; Palamaner Subash Shantha, G; Vaughan Sarrazin, MS | 1 |
| Colquhoun, D; Freedman, B; Ortiz, M; Simons, LA; Waterhouse, BJ | 1 |
| Barmparas, G; Bosarge, P; Brown, CV; Bukur, M; Carrick, MM; Catalano, RD; Coimbra, R; Holly-Nicolas, J; Inaba, K; Kaminski, S; Klein, AL; Kobayashi, L; Kopelman, T; Ley, EJ; Martinez, EM; Moore, FO; Murry, J; Nirula, R; Paul, D; Quick, J; Rivera, O; Schreiber, M | 1 |
| Bo, M; Di Minno, G; Di Pasquale, G; Genovesi, S; Molteni, M; Toni, D; Verdecchia, P | 1 |
| Bai, Y; Lip, GYH; Shantsila, A | 1 |
| Arias-Jaramillo, DR; Gaviria-Mendoza, A; Machado-Alba, JE | 1 |
| Beauchesne, MF; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Turgeon, MH | 1 |
| Schwartz, JB | 2 |
| Alexander, JH; Lopes, RD; Vora, AN | 1 |
| Lim, WS; Zhao, YJ | 1 |
| Graham, DJ; Kelman, JA; Wernecke, M | 1 |
| Parks, AL; Redberg, RF | 1 |
| Gotoh, S; Kuwashiro, T; Nakamura, A; Nakanishi, Y; Okada, Y; Takaguchi, G; Tomoda, M; Yasaka, M | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Chan, YH; Kuo, CT | 1 |
| Dörks, M; Herget-Rosenthal, S; Hoffmann, F; Jobski, K | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Angeli, F; Brueckmann, M; Connolly, SJ; Di Pasquale, G; Ezekowitz, MD; Kleine, E; Lip, GYH; Mazzotta, G; Reboldi, G; Verdecchia, P; Wallentin, L; Yusuf, S | 1 |
| Churilov, L; Hardidge, AJ; Suen, K; Westh, RN | 1 |
| Bowen, JM; Burke, N; Campbell, K; Holbrook, A; Jegathisawaran, J; Tarride, JE | 1 |
| Gupta, K; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Trocio, J; You, M | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Hylek, E; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Shrader, P; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Aiello, A; Aspromonte, N; Colivicchi, F; Di Fusco, SA; Santini, M; Tubaro, M | 1 |
| Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
| Andrews, G; Annavarapu, S; Costantino, ME; Gandhi, PK; Ghate, SR; Moretz, C; Reynolds, SL; Sander, S; Sheer, R; Wang, C | 1 |
| Kido, K; Scalese, MJ | 1 |
| Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L | 1 |
| Imberti, D; Mastroiacovo, D | 1 |
| Arora, P; Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Alberts, MJ; Bunz, TJ; Coleman, CI; Peacock, WF | 1 |
| Cheong, JS; Chung, JY; Kang, HG; Lee, SJ | 1 |
| Sugiyama, T | 1 |
| Chan, EW; Lau, WCY; Wong, ICK | 1 |
| Hu, SJ; Wu, T; Xu, WW | 1 |
| Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Jolobe, OMP | 1 |
| Lip, GYH; Makaritsis, K; Michel, P; Ntaios, G; Papavasileiou, V; Vemmos, K | 1 |
| Gersh, BJ; Hargraves, I; Montori, VM; Noseworthy, PA; Shah, ND; Yao, X | 1 |
| Ariansen, I; Ellekjær, H; Furu, K; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 1 |
| Alonso, A; Norby, FL | 1 |
| Chan, EW; Lau, WCY; Leung, WK; Li, X; Lip, GYH; Man, KKC; Siu, CW; Wong, ICK | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C | 1 |
| Calkins, H; Nordaby, M | 1 |
| Seligman, SJ | 1 |
| Larsen, JM; Løfgren, B; Pareek, M | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Izumiya, Y; Kaikita, K; Kojima, S; Ogawa, H; Sueta, D; Takashio, S; Tsujita, K; Yamabe, H; Yamamoto, E; Yamamuro, M | 1 |
| Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Fogerty, AE; Oertel, LB | 1 |
| Petrasko, M; Petraskova, T; Raizada, A | 1 |
| Favaloro, EJ; Lippi, G; Pasalic, L | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Curtice, T; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Luo, X; Mardekian, J; Menges, B; Trocio, J | 1 |
| Abarca, J; Adeboyeje, G; Barron, JJ; Crawford, G; Redberg, R; Rosenberg, A; Sylwestrzak, G; White, J | 1 |
| Ashton, V; Crivera, C; Germain, G; Laliberté, F; Lefebvre, P; McHorney, CA; Peterson, ED; Schein, JR; Wynant, W | 1 |
| Izumi, N; Katada, J; Kohsaka, S; Murata, T; Terayama, Y; Wang, F | 1 |
| Bhave, PD; Bhise, V; Chaikriangkrai, K; Deshmukh, A; Giudici, M; Horwitz, PA; Inampudi, C; Kumar, AA; Mentias, A; Mickelsen, S; Oral, H; Palamaner Subash Shantha, G; Pancholy, S; Patel, N; Vaughan Sarrazin, MS | 1 |
| Hernandez, I; Saba, S; Zhang, Y | 2 |
| Alonso, A; Bengtson, LGS; Chamberlain, AM; Chen, LY; Lutsey, PL; MacLehose, RF; Norby, FL; Rapson, I | 1 |
| Reiffel, JA | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Griffiths, CL; Hicks, S; Livengood, SJ; Vestal, ML | 1 |
| Evans, J; Wormald, R | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Rubboli, A | 1 |
| Galanter, WL; Lee, TA; Manzoor, BS; Nutescu, EA; Sharp, LK; Walton, SM | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Chaturvedi, S; Diener, HC; Hohnloser, SH; Molina, CA; Selim, MH | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Lane, DA; Oldgren, J; Proietti, M; Roldan, V; Wallentin, L; Yusuf, S | 1 |
| Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E | 1 |
| Basto, AN; Fewel, NP; Stock, EM; Ta, M; Vo, K | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
| Cheetham, TC; Gagne, JJ; Go, AS; Goulding, MR; Graham, DJ; Houstoun, M; Izem, R; Mott, K; Reichman, ME; Singer, DE; Southworth, MR; Sung, SH; Toh, S; Zhang, R | 1 |
| Eek, AK; Granas, AG; Øie, E | 1 |
| Gersh, BJ; Nath, KA; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Tangri, N; Yao, X | 1 |
| Connolly, SJ; Walsh, M | 1 |
| Brodie, MM; Newman, JC; Rockey, DC; Smith, T | 1 |
| Bhatt, NR; Davis, NF; Flynn, RJ; Manecksha, RP; McDermott, T; Nolan, WJ; Thomas, AZ | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schüler, E; Schulman, S | 1 |
| Ahn, Y; Cho, JG; Cho, JY; Hong, YJ; Hyun, DY; Jeong, MH; Kim, JH; Kim, KH; Kim, MC; Kim, Y; Lee, KH; Lee, N; Oh, SS; Park, HJ; Park, HW; Park, JC; Sim, DS; Won, J; Yoon, HJ; Yoon, NS | 1 |
| Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L | 1 |
| Miano, T; Pan, W; Uyhazi, KE; VanderBeek, BL | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Glynn, RJ; Krumme, AA; Kulldorff, M; Ortiz, AS; Pawar, A; Schneeweiss, S | 1 |
| Ishikawa, T; Moroi, J; Nakase, T | 1 |
| Fujino, T; Hamai, A; Hara, F; Harada, M; Ikeda, T; Kabuki, T; Ohara, H; Wakakura, S | 1 |
| Elder, J; Fu, AC; Jain, R; Lim, J; Sander, SD; Tan, H; Wang, C | 1 |
| Steuber, T | 1 |
| Chinushi, M; Fuse, I; Hasegawa, Y; Iijima, K; Izumi, D; Minamino, T; Otuki, S; Sato, A; Suda, M; Yagihara, N | 1 |
| Cheng, HM; Hsu, CC; Hsu, PF; Huang, CJ; Sung, SH; Tu, ST; Yu, BH | 1 |
| Boo, YL; Hoo, FK; Koh, KW; Kolanthaivelu, J; Ng, YP; P'ng, HS; Roslan, A; Yap, LB; Yap, SH | 1 |
| Han, F; He, H; Ke, B; Li, X; Li, Y; Zeng, Y | 1 |
| Balsam, P; Bednarski, J; Filipiak, KJ; Grabowski, M; Kowalczuk, A; Kołtowski, Ł; Lodziński, P; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Ogińska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Jesus, PAP; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S | 1 |
| Steurer, J | 1 |
| Fischer, MA; Franklin, JM; Gagne, JJ; Glynn, RJ; Huybrechts, KF; Schneeweiss, S; Wang, SV | 1 |
| Cannon, CP; Lip, GYH; Oldgren, J | 1 |
| Karnieg, T; Wang, X | 1 |
| Dekkers, T; Kramers, C; Lafeber, M | 1 |
| Baduashvili, A; Evans, AT | 1 |
| Jones, WS; Piccini, JP | 1 |
| Choudhry, NK; Gagne, JJ; Najafzadeh, M; Schneeweiss, S; Wang, SV | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Chi, NF; Chien, LN; Chien, SC; Ko, Y; Wang, Y | 1 |
| Aisenberg, J; Brueckmann, M; Chatterjee-Murphy, P; Connolly, S; Desai, J; Ezekowitz, M; Flack, KF; Ilgenfritz, J; Kolb, JM; Reilly, P; Wallentin, LC | 1 |
| Adeboyeje, G; Barron, JJ; Charlton, B; Grady, D; Redberg, RF; Shin, J | 1 |
| Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Chan, YH; Chang, SH; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wang, CL; Wu, LS; Yeh, YH | 1 |
| Akintoye, E; Alvarez, P; Briasoulis, A; Inampudi, C; Panaich, S; Vaughan-Sarrazin, M | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Bunz, TJ; Coleman, CI; Martinez, BK; Sood, NA | 1 |
| Kamble, S; Kawabata, H; Lip, GYH; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Boswell, R; Pearson, GJ | 1 |
| Garzon, J; Jaramillo, L; Mendoza, L; Mendoza-Sanchez, J; Quiroga, A; Rangel, L; Silva, F | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Caria, J; Coutinho, JM; Dentali, F; Desch, M; Diener, HC; Ferro, JM; Fraessdorf, M; Huisman, H; Kobayashi, A | 1 |
| Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Jain, N; Reilly, RF | 1 |
| Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Andrews, GA; Annavarapu, S; Arora, P; Gandhi, PK; Li, Y; Moretz, C; Sander, SD; Wang, C | 1 |
| Fredgart, M; Gill, S | 1 |
| Kim, M; Kim, MS; Kim, S; Ko, YJ; Lee, J; Park, BJ; Park, K; Yang, BR | 1 |
| Bittinger, L; Curtis, C; Pol, D; Ramkumar, S | 1 |
| Durand, M; Johnson, S; Matteau, A; Sinyavskaya, L | 1 |
| Chan, YH; Chang, CY; Chang, SH; Hsieh, MY; Kuo, CF; Kuo, CT; See, LC; Tu, HT; Yeh, YH | 1 |
| Adriaenssens, T; Sinnaeve, P | 1 |
| Bohn, J; Cosgrove, A; Desai, RJ; Gagne, JJ; Jin, Y; Karami, S; Kennedy, A; Kim, C; Kim, J; Major, JM; Niman, A; Ouellet-Hellstrom, R; Toh, S; Wang, SV; Wyss, R | 1 |
| Dobrev, D; Fender, AC | 1 |
| Coupland, C; Hill, T; Hippisley-Cox, J; Vinogradova, Y | 1 |
| Ferreira, M; Feuring, M; Fraessdorf, M; Huisman, MV; Klok, FA | 1 |
| Chen, HM; Lai, CL; Liao, MT; Lin, TT | 1 |
| Alviz, I; Avendano, R; Cerna, L; Cerrud-Rodriguez, RC; Di Biase, L; Diaz, JC; Grupposo, V; Kirchhof, P; Kumar, S; Michaud, GF; Natale, A; Romero, J; Taveras, J | 1 |
| Azboy, I; Groff, H; Parvizi, J | 1 |
| Gu, ZC; Pu, J; Wei, AH | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Andrade, LAP; Andrade, MQS; Andrade, MVS; Bispo, AF; Feitosa, GS; Feitosa-Filho, GS; Freitas, LA | 1 |
| Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA | 1 |
| Kido, K; Ngorsuraches, S | 1 |
| Bakkehøi, G; Eek, AK; Stenberg-Nilsen, H; Strøm, BO | 1 |
| Calabrese, V; Colaiori, I; Creta, A; Di Sciascio, G; Ioannou, A; Picarelli, F; Providência, R; Ragni, L; Ricciardi, D; Scordino, D | 1 |
| Carlsen, SM; Giannadakis, C; Gulati, AM; Gulati, S; Jakola, AS; Jensberg, H; Madsbu, MA; Salvesen, Ø; Solheim, O; Øie, LR | 1 |
| Bawa, H; Dirschl, DR; Luu, HH; Weick, JW | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Dannenberg, L; Kelm, M; Petzold, T; Polzin, A; Wolff, G; Zeus, T | 1 |
| Bai, R; Chang, SS; Chen, AH; Dong, JZ; Du, X; Geng, YP; Guo, XY; Jiang, CX; Lan, DH; Li, SN; Liu, N; Long, DY; Ma, CS; Sang, CH; Tang, RB; Wang, W; Xia, SJ; Yu, RH; Zheng, D | 1 |
| Franchino-Elder, J; Gilligan, AM; Henriques, C; Sainski-Nguyen, A; Sander, S; Smith, DM; Song, X; Wang, C; Wilson, K | 1 |
| Bertlich, M; Bootz, F; Eichhorn, KW; Freytag, S; Gräff, I; Horlbeck, F; Jakob, M; Schafigh, D; Send, T | 1 |
| Lip, GYH | 1 |
| Hiremath, JS; Trailokya, A | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| An, GV; Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K | 1 |
| Ansell, JE; Blanco, R; Fonarow, GC; Freeman, JV; Gersh, BJ; Go, AS; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Naccarelli, G; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Singer, DE; Thomas, LE; Washam, JB | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Lehre, I; Molden, E; Ranhoff, AH; Viktil, KK | 1 |
| Hu, A; Niu, J; Winkelmayer, WC | 1 |
| Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB | 1 |
| Cheon, K; Cho, HJ; Choi, HY; Han, SW; Heo, JH; Jung, YH; Kim, YD; Lee, HS; Lee, KY; Nam, HS; Park, HJ; Park, JH | 1 |
| Fanaroff, AC; Ohman, EM | 1 |
| Hirakawa, T; Ishida, K; Koretsune, Y; Kuroki, D; Ono, Y; Sumida, T; Urushihara, H; Yamashita, T; Yasaka, M | 1 |
| Baker, CL; Dhamane, AD; Dina, O; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Rosenblatt, L; Russ, C | 1 |
| Bonde, AN; Fosbøl, EL; Gislason, GH; Køber, L; Lamberts, M; Olesen, JB; Rørth, R; Torp-Pedersen, C; Vinding, NE | 1 |
| Chung, CP; Daugherty, JR; Dupont, WD; Murray, KT; Ray, WA; Smalley, WE; Stein, CM | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Baser, O; Deitelzweig, S; Friend, K; Gupta, K; Hamilton, M; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Masseria, C; Nadkarni, A; Pan, X | 1 |
| Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Akamatsu, Y; Hayashi, T; Kameyama, M; Karibe, H; Narisawa, A | 1 |
| Campodonico, P; Guiddo, G; Lerza, R; Malerba, M; Minuto, P; Motta, G; Riccardi, A; Spinola, MB | 1 |
| Bae, HJ; Chung, I; Gwak, DS; Han, MK; Kang, JH; Kim, BJ; Kim, BK; Woo, HG | 1 |
| Guo, X; Liu, Y; Sun, Z; Xu, Y; Zhang, Y | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Ako, J; Fukaya, T; Kimura, T; Kozuma, K; Morino, Y; Nakao, K; Okazaki, K; Okumura, K | 1 |
| Chaudhury, P; Mentias, A; Shantha, G; Vaughan Sarrazin, MS | 1 |
| Huang, Y; Que, D; Wang, L; Wu, S; Xie, S; Xu, Y; Yau, TO | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Biss, B; Calkins, H; Gerstenfeld, EP; Hohnloser, SH; Kleine, E; Nordaby, M; Okumura, K; Schilling, R; Verma, A; Willems, S | 1 |
| Bartels, DB; Franklin, JM; Gopalakrishnan, C; Huybrechts, KF; Kulldorff, M; Schneeweiss, S; Zint, K | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Jesus, P; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG; Souza, IFB | 1 |
| Ariano, C; De Vecchis, R | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| DuCott, A; Gagne, JJ; Maro, JC; Petrone, AB; Toh, S | 1 |
| Cha, MJ; Choi, EK; Kim, HM; Kwon, JM; Lee, SY; Oh, S; Park, CS | 1 |
| Alak, A; Brueckmann, M; Connolly, SJ; Ezekowitz, M; Fräßdorf, M; Healey, JS; Hohnloser, SH; Reilly, P; Yusuf, S | 1 |
| Breuer, L; Engelhorn, T; Kallmünzer, B; Macha, K; Marsch, A; Schwab, S; Siedler, G; Strasser, EF | 1 |
| Arcadi, FA; Calabrò, RS; Casella, C; Genovese, C; Giorgianni, R; Marino, S; Naro, A; Portaro, S | 1 |
| Amin, A; Dhamane, A; Di Fusco, M; Friend, K; Garcia Reeves, AB; Keshishian, A; Li, X; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Pickett, JD | 1 |
| Bunch, TJ; Crandall, B; Cutler, M; Day, JD; Jacobs, V; Mallender, C; May, H; Olson, J; Osborn, J; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Ahn, JY; Bang, CS; Cho, YK; Joo, MK; Jung, HK; Kim, BJ; Kim, BW; Kim, JS; Lee, BE; Lee, JH; Park, CH; Park, JM; Yang, HJ | 1 |
| Bis, B; Calkins, H; Gerstenfeld, EP; Hohnloser, SH; Kleine, E; Nordaby, M; Okumura, K; Schilling, R; Verma, A; Willems, S | 1 |
| Aonuma, K; Goya, M; Harada, T; Hirao, K; Kihara, Y; Nakahara, S; Nakano, Y; Nogami, A; Nuruki, N; Origasa, H; Otani, R; Sekiguchi, Y; Yoshida, K; Yoshida, Y | 1 |
| Arbel, M; Ayata, C; Bacskai, BJ; Böhm, M; Boulouis, G; Endres, M; Fischer, P; Frosch, MP; Greenberg, SM; Qin, T; Schlunk, F; Tamim, I | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, H; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, YS; Park, HW; Park, J; Park, JK; Shim, J; Uhm, JS | 1 |
| Alings, M; Connolly, SJ; Dorresteijn, JAN; Eikelboom, JW; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; van der Leeuw, J; Visseren, FLJ | 1 |
| Caughey, G; Duszynski, K; Kalisch Ellett, LM; Kerr, M; Pratt, NL; Ramsay, E; Roughead, EE; Shakib, S | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Dina, O; Gupta, K; Keshishian, A; Mardekian, J; Nadkarni, A; Shank, TC; Trocio, J; Zhang, Q | 1 |
| Cha, MJ; Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Olshansky, B | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Hinotsu, S; Kano, MR; Kitamura, Y; Koyama, T; Miller, MW; Ogawa, A; Ohshima, A; Sendo, T; Tanaka, HY; Zamami, Y | 1 |
| López-López, JA; Thom, H; Welton, NJ | 1 |
| Elder, M; Hung, YC; Morris, A | 1 |
| Butt, JH; Fosbøl, EL; Garcia, D; Køber, L; Li, A; Peterson, ED; Torp-Pedersen, C; Xian, Y | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kiss, RG; Kleine, E; Lip, GYH; Navarro Estrada, JL; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM | 1 |
| Ariansen, I; Ellekjær, H; Karlstad, Ø; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 1 |
| Buscarini, E; Coote, N; Droege, F; Dupuis-Girod, S; Fialla, AD; Geisthoff, U; Kjeldsen, A; Lenato, GM; Mager, HJ; Manfredi, G; Millar, CM; Pagella, F; Post, MC; Sabbà, C; Shovlin, CL; Suppressa, P; Sure, U; Torring, PM; Ugolini, S | 1 |
| Alasheev, A; Canhão, P; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Frässdorf, M; Huisman, H; Karpov, D; Kobayashi, A; Nagel, S; Posthuma, L; Reilly, P; Roriz, JM | 1 |
| Dong, J; Du, X; Ma, C; Yang, Y | 1 |
| Blin, P; de Pouvourville, G; Karam, P | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Bailey, E; Bollu, PC; Dyer, N; Govindarajan, R; Nagarajan, E; Sivaraman, M; Yelam, A | 1 |
| Adabala, N; Bommana, S; Di Biase, L; Gianni, C; Gopinathannair, R; Khalafi, M; Lakkireddy, D; Lakkireddy, P; Maybrook, R; Mohanty, S; Natale, A; Parikh, V; Pillarisetti, J; Reddy, MY; Reddy, S; Saksena, S | 1 |
| Manolopoulos, VG; Ragia, G | 1 |
| Alonso, A; Chen, LY; Diem, SJ; Ensrud, KE; Lutsey, PL; MacLehose, RF; Norby, FL | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Welt, FGP | 1 |
| Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Kanorskii, SG | 1 |
| Bartels, DB; Gopalakrishnan, C; Gurusamy, VK; Huybrechts, KF; Landon, J; Schneeweiss, S; Zint, K | 1 |
| Goyal, N; Mowla, A; Sadighi, A; Seiffge, DJ; Shahjouei, S; Tsivgoulis, G; Wang, M; Zand, R | 1 |
| Hsu, JY; Huang, HK; Lin, SM; Liu, PP; Loh, CH; Peng, CC; Wang, JH; Yeh, JI | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Bhatt, DL; Cannon, CP; Ducrocq, G; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Chaiyakunapruk, N; Dilokthornsakul, P; Hollingworth, W; Jahan, NK; Kongpakwattana, K; Lai, NM; Nathisuwan, S; Ng, SS | 1 |
| Buda, S; Degli Esposti, L; Perrone, V; Piovaccari, G; Saragoni, S | 1 |
| Albert, L; Bejjani, A; Coons, JC; Iasella, CJ | 1 |
| Bernstein, RA; Clark, CL; Douketis, J; Fanikos, J; Fermann, GJ; Fiore, GJ; Frost, A; Jahromi, B; Johnson, C; Merli, G; Peacock, WF; Pollack, CV; Silber, S; Villines, TC | 1 |
| Devilbiss, Z; O'Connor, F | 1 |
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Chen, N; Holbrook, A; Lee, M; Leenus, A; Liu, J; Mbuagbaw, L; Thabane, L; Wang, M | 1 |
| Cao, Y; Jiang, W; Yang, Y | 1 |
| Bhatt, DL; Cannon, CP; Maeng, M; Miede, C; Nordaby, M | 1 |
| Shan, C; Yu, L; Yu, Z | 1 |
| Ho, KH; Leng, G; van Hove, M | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Al Banny, R; Husain, A; Qader, AM; Qader, KM; Sridharan, K | 1 |
| Bernelli, C; Danzi, GB; Olivotti, L; Paonessa, K | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Brooks, MM; Glynn, NW; Hernandez, I; Saba, S; Yang, L; Zhang, Y | 1 |
| Böhm, M; Brueckmann, M; Eikelboom, JW; Ezekowitz, M; Fräßdorf, M; Hijazi, Z; Hohnloser, SH; Mahfoud, F; Schmieder, RE; Schumacher, H; Wallentin, L; Yusuf, S | 1 |
| Modukuru, VR; Naderan, M; Shoar, N; Shoar, S | 1 |
| Chan, EW; Cheung, CL; Lam, JKY; Lau, WCY; Lee, ACH; Lip, GYH; Man, KKC; Sing, CW; Siu, CW; Wong, ICK | 1 |
| Mastroroberto, P; Santarpino, G | 1 |
| Liu, X; Sun, Y; Xu, Y | 1 |
| Lip, GYH; Shantsila, A; Shantsila, E | 1 |
| Blais, JE; Chan, EW; Chen, EYH; Chui, CSL; Lau, WCY; Mok, MT; Seto, WK; Suh, IH; Wong, ICK; Yan, VKC; Zhao, J | 1 |
| Andersen, PS; Bruun, NE; Bundgaard, H; Butt, JH; Fosbøl, EL; Gerds, TA; Gislason, GH; Iversen, K; Køber, L; Larsen, AR; Olesen, JB; Petersen, A; Skov, RL; Torp-Pedersen, C; Verhamme, P | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Pazan, F; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Douketis, J; Kaplovitch, E; Shaw, JR | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Falissard, B; Gollety, S; Hanon, O; Jacoud, F; Lefevre, C; Mahé, I; Nolin, M; Steg, PG; Van Ganse, E | 1 |
| Bhatt, DL; Cannon, CP; Godoy, LC; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nicolau, JC; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Le, T; Pasciolla, S; Wright, K; Zizza, LF | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Edwards, JK; Lund, JL; Poole, C; Simpson, RJ; Stürmer, T; Webster-Clark, M | 2 |
| Doyama, H; Fujishiro, M; Fujita, T; Hasatani, K; Hatta, W; Hiasa, Y; Hikichi, T; Igarashi, K; Iguchi, M; Inoue, T; Kawaguchi, K; Kitamura, K; Kuribayashi, S; Mikami, T; Morita, Y; Nishida, T; Nishikawa, J; Oda, I; Sumiyama, K; Sumiyoshi, T; Tomida, H; Tsuji, Y; Uraoka, T; Yada, T; Yamamoto, K; Yanagitani, A; Yoshio, T | 1 |
| Gong, JH; Liu, GJ; Sun, ZQ; Zhou, F | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Goldhaber, SZ; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I; Zint, K | 1 |
| Jin, H; Wang, L; Zhi, H; Zhou, W; Zhu, K | 1 |
| Bendszus, M; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Huisman, H; Jansen, O; Kobayashi, A; Miede, C; van der Veen, B | 1 |
| Gommans, E; Grouls, RJE; Houterman, S; Kerkhof, D; Simmers, T; Van der Linden, C | 1 |
| Eikelboom, JW; Eriksson, N; Ezekowitz, MD; Granger, CB; Hijazi, Z; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Amano, Y; Fujishiro, H; Harada, H; Hayasaka, K; Iwaki, T; Katsuyama, Y; Kushiyama, Y; Maeda, G; Miyaoka, Y; Murakami, D; Nakahara, R; Ujihara, T; Yuki, T | 1 |
| Chiu, D; Weinberger, J | 1 |
| Andreoli, L; Barcellona, D; Cafolla, A; De Micheli, V; Denas, G; Falanga, A; Fierro, T; Gerosa, M; Ghirarduzzi, A; Gresele, P; Hoxha, A; Martinelli, I; Pengo, V; Prisco, D; Silvestri, E; Testa, S; Tincani, A; Tosetto, A | 1 |
| Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B | 1 |
| Ali, H; Balla, C; Bonitta, G; Briani, M; Cappato, R; Chiarito, M; Furlanello, F; Giustozzi, M; Lodigiani, C; Lupo, P; Riva, L; Stefanini, G | 1 |
| Barrios, V; Escobar, C | 1 |
| Böhm, M; Millenaar, D | 1 |
| Hardy, LJ; Khan, AA; Lau, YC; Lip, GYH; Philippou, H; Shantsila, E | 1 |
| Bereznicki, LR; Bezabhe, WM; Curtain, C; Peterson, GM; Radford, J; Salahudeen, MS; Wimmer, BC | 1 |
| Ham, SA; Micic, D; Sengupta, N; Tapaskar, N | 1 |
| Carney, G; Durand, M; Eltonsy, S; Filion, KB; Fisher, A; Jun, M; Kuo, IF; Matteau, A; Pang, M; Paterson, JM; Quail, J; Renoux, C; Schnitzer, ME | 1 |
| Dvorackova, S; Jirsova, E; Kolar, J; Kubena, AA; Mala-Ladova, K; Maly, J; Steurbaut, S; Zimcikova, E | 1 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Ishizawa, K; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
| Holzgreve, H | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN | 1 |
| Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
| Lee, EM; Tan, VH; Tan, YC; Tiew, WJ; Wong, VL | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Jiang, YR; Liao, JN; Tsai, CT | 1 |
| Brahmbhatt, B; Devani, K; Radadiya, D; Reddy, C | 1 |
| Cui, C; Cui, X; Li, D; Liu, Y; Wei, H | 1 |
| Beharry, JM; Hanger, HC; Mee, HJ; Wilkinson, TJ; Wu, TY | 1 |
| Chan, FK; Guo, CL; Lam, KL; Lau, LH; Mak, JW; Ng, SC; Wong, GL; Wong, SH; Yip, TC | 1 |
| Barnathan, E; Freedman, A; Larbi, L; Rao, G; Shoaibi, A; Truong, HQ; Wang, L; Weaver, J; Wildgoose, P; Wu, S; Yuan, Z | 1 |
| Côté, R; Dorais, M; Martel, MJ; Perreault, S; Qazi, JZ; Schnitzer, ME | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Bauwens, M; Brandenburg, V; Briedé, JJ; Bröker, V; Bucerius, J; Dijkgraaf, I; Dweck, MR; Jennen, D; Leenders, P; Mottaghy, F; Reutelingsperger, CP; Schurgers, LJ; Spronk, HMH; van Gorp, RH; van Ryn, J | 1 |
| Chen, HY; Chou, KJ; Huang, CW; Lee, PT; Lin, PC; Ou, SH; Su, YC | 1 |
| Aguiar de Sousa, D; Bendszus, M; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Huisman, H; Jansen, O; Kobayashi, A; Miede, C; Neto, LL | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Ashton, V; Berger, JS; Jung, Y; Kharat, A; Laliberté, F; Lefebvre, P; Lejeune, D; Moore, KT | 1 |
| Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S | 1 |
| D'Elia, E; Di Marco, F; Falanga, A; Gori, M; Grosu, A; Iorio, A; Lorini, FL; Senni, M | 1 |
| Chan, EWY; Cheung, BMY; Cheung, CL; Lau, WCY; Li, GHY; Lip, GYH; Sing, CW; Tan, KCB; Wong, ICK | 1 |
| Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD | 1 |
| Chang, RY; Hu, YF; Huang, CY; Lee, CW; Lee, TM; Liu, ME; Yeh, HI | 1 |
| Bhatt, DL; Cannon, CP; Gabriel Steg, P; Halvorsen, S; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Peterson, BE; Ten Berg, JM; Zeymer, U | 1 |
| Duvanova, SP; Filimonov, KM; Gorbunova, EV; Makarov, SA; Mamchur, SE | 1 |
| Dong, YX; Gao, LJ; Li, WW; Ma, CM; Wang, N; Xia, YL; Xiao, XJ; Yang, MH; Yin, XM; Yu, XH; Zhang, RF | 1 |
| Anoopkumar-Dukie, S; Badrick, T; Bernaitis, N | 1 |
| Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 1 |
| Agudo-Fernández, S; Calvo Morillas, I; Castaño Milla, C; González Blanco, A; Olmos Jerez, JA; Sancho Del Val, L | 1 |
| Anderson, A; Eworuke, E; Gassman, A; Hou, L; Huang, TY; Moeny, D; Waldron, P; Wong, HL; Zhang, R | 1 |
| Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS | 1 |
| Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Eccleston, DS; Hohnloser, SH; Kim, JM; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Hong, BY; Jung, J; Kim, JS; Lim, SH; Park, J; Park, JG | 1 |
| Bennie, M; Forslund, T; Hallas, J; Haug, U; Hellfritzsch, M; Hjemdahl, P; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Kollhorst, B; Komen, JJ; Mantel-Teeuwisse, AK; Mueller, T; Olesen, M; Pottegård, A; Schink, T; Voss, A; Wettermark, B | 1 |
| Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Han, KD; Kim, BS; Kim, HK; Kim, YJ; Lee, H; Lee, HJ; Lee, SP; Park, JB | 1 |
| Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
| Abdelgawwad, K; Brescia, CW; Coleman, CI; Costa, OS; O'Donnell, B; Sood, N; Vardar, B | 1 |
| Connor, DE; Hayward, CS; Jain, P; Jansz, P; Joseph, J; Kerr, NP; Muthiah, K; Rao, SD; Robson, D; Shehab, S | 1 |
| Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS | 1 |
| Atar, D; Rubboli, A | 1 |
| Eriksson, H; Ghanima, W; Kahn, SR; Morrison, D; Sandset, PM; Schulman, S; Wik, HS | 1 |
| Bessette, LG; Gagne, JJ; Glynn, RJ; Kim, DH; Lee, H; Pawar, A; Schneeweiss, S | 1 |
| Jiang, H; Jiang, Y; Lv, J; Ma, H; Zeng, H | 1 |
| Chen, CY; Chu, CC; Huang, YL | 1 |
| Deitelzweig, S; Dhamane, AD; Ferri, M; Jiang, J; Kang, A; Keshishian, AV; Klem, C; Lip, GYH; Luo, X; Yuce, H; Zhang, Y | 1 |
| Badve, SV; Beaubien-Souligny, W; Blum, D; Dorian, P; Garg, AX; Harel, Z; Jandoc, R; Jeyakumar, N; Jun, M; Kitchlu, A; McArthur, E; Silver, SA; Smyth, B; Sood, MM; Wald, R; Yan, AT | 1 |
| Ader, J; Desai, NR; Jones, PG; Reinhardt, SW; Spertus, JA; Tang, Y | 1 |
| Ageno, W; Casella, IB; Chee, KH; Goldhaber, SZ; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I | 1 |
| Abdulsattar, W; Al-Abdouh, A; Alom, M; Assaly, R; Ayesh, H; Beran, A; Hamouda, D; Khuder, SA; Mhanna, M; Sajdeya, O; Srour, O | 1 |
| An, J; Duan, L; Huang, CW; Lee, MS; Sim, JJ | 1 |
| Everington, T; Husted, M; McKeague, L; Sly, D | 1 |
| Ahuja, N; Ashraf, R; Bharati, J; Rajarajen, AP | 1 |
| Albracht, DE; Bhushan, S; Mansi, IA | 1 |
| Rodwin, BA | 1 |
| Barnes, GD; Cuker, A; Dawwas, GK; Lewis, JD | 1 |
| Garg, J; Shah, S | 1 |
| Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Hernandez, I; Keshishian, A; Russ, C; Tsai, WL; Yuce, H | 1 |
| Guo, CL; Lee, APW; Shahzada, TS | 1 |
| Chu, H; Du, X; Feng, M; Fu, G; He, B; Liu, J; Wang, B; Wang, Z; Yu, Y; Zhuo, W | 1 |
| Dong, W; Jiang, M; Nie, X; Zhou, H | 1 |
| Luijkx, J; van 't Hof, A; Winkler, P | 1 |
| Alvarez, P; Chaudhury, P; Desai, MY; Hanna, M; Kanj, M; Mentias, A; Moudgil, R; Nakhla, M | 1 |
| Aizawa, T; Hojo, S; Kaneda, K; Kato, M; Kawaji, T; Kimura, T; Kushiyama, A; Miki, S; Morimoto, T; Nakatsuma, K; Yaku, H; Yokomatsu, T | 1 |
| de Vries, TI; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; Visseren, FLJ; Westerink, J | 1 |
| Ciminata, G; Deidda, M; Geue, C; Kreif, N; Langhorne, P; Wu, O | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
| Bereznicki, LR; Bezabhe, WM; Kefale, AT; Peterson, GM | 1 |
| Zakrocka, I; Załuska, W | 1 |
| Caviness, LA; Howard-Thompson, A; Wassell, KM | 1 |
| Horwitz, H; Jimenez-Solem, E; Nyeland, ME; Schelde, AB; von Osmanski, BI | 1 |
| da Silva, RMFL | 1 |
| Hirohisa, I; Hiroshi, I; Hiroyuki, N; Masayori, S; Natsuko, SY; Yutaka, I | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E; Tryggvason, G | 1 |
| Bang, OY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, MY; On, YK; Park, YJ; Ryu, J; Suh, HS | 1 |
| Cho, MS; Choi, KJ; Kang, DH; Kim, DH; Kim, J; Kim, M; Kim, SJ; Lee, S; Lee, SA; Nam, GB; Song, JM | 1 |
| Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y | 1 |
| Alkhameys, S; Barrett, R | 1 |
| Chung, MK; Dukes, J; Ezekowitz, MD; Gengler, BE; Gopinathannair, R; Lakkireddy, D; Lip, GYH; Mar, PL; Miletello, M; Noseworthy, PA; Olshansky, B; Perez, A; Reiffel, J; Tisdale, JE | 1 |
| Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR | 1 |
| Chang, A; Harper, P; Stephens, M | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, Q; Yu, M; Zong, L | 1 |
| Ajao, A; Connolly, JG; Cosgrove, A; Eworuke, E; Kolonoski, J; Mohamoud, M; Shapira, O; Zhang, R | 1 |
| Al Kasasbeh, M; Al-Abdouh, A; Barbarawi, M; Barbarawi, O; Corcoran, J; Mhanna, M; Obeidat, K; Pickett, CC | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E | 1 |
| Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
| Chaudhury, P; Desai, MY; Harb, S; Johnston, D; Kapadia, S; Menon, V; Mentias, A; Michael, M; Nakhla, S; Saad, M; Saliba, W; Svensson, L; Wazni, O | 1 |
| Bai, Z; Chen, H; Cheng, G; Ning, H; Yang, N; Zhao, Y; Zou, M | 1 |
| Bessette, LG; Schneeweiss, S; Sreedhara, SK; Wang, SV | 1 |
| Ktenopoulos, N; Lionaki, S; Rallidis, LS; Sagris, M; Theofilis, P | 1 |
| Bito, A; Fujii, H; Fukuda, M; Murata, N; Narahara, Y | 1 |
| Bloom, B; Cohen-Aubart, F; Freund, Y | 1 |
| Beyene, K; Chan, AHY; Gong, J; Hayes, M; Munevar Aquite, O; Schauer, C; Wei, H | 1 |
| Bani Hani, Z; S H Abrahim, M; Sofola-James, O | 1 |
| Björnsson, ES; Hreinsson, JP; Ingason, AB | 1 |
| Cho, MS; Choi, KJ; Kang, DH | 1 |
| Ali, AK; Duffield, S; Gatto, N; Gibbs, L; Govil, P; Jaksa, A; Jonsson, P; Kent, S; Kincaid, L; Patrick, AR; Rowark, S; Sharma, M | 1 |
| Amado, DK; Borges-Junior, FA; Brucki, SMD; Calderaro, D; Caramelli, B; Caramelli, P; Cardozo, FAM; Escalante-Rojas, MC; Gualandro, DM; Magalhães, IR; Matheus, MG; Nitrini, R; Pastana, AF; Rodrigues, ACO; Spera, RR; Tavares, CAM; Yu, PC | 1 |
| Chen, J; Chen, M; Fang, Z; Guan, C; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Badve, SV; Deague, J; Dundon, BK; Hammett, C; Joseph, JE; Kerr, PG; Lo, S; Perkovic, V; Tran, HA; Wong, A | 1 |
| Ha, N; Hess, R; Mouland, E; Renner, E; Sutter-Long, D | 1 |
| Alsultan, MM; Costa, LSD; Guo, JJ; Hincapie, AL | 1 |
| Borhani-Haghighi, A; Ghafari Darab, M; Goudarzi, Z; Hayatbakhsh, A; Jafari, M; Karimzadeh, I; Keshavarz, K; Vazin, A | 1 |
| Boivin Proulx, LA; Dorais, M; Legault, C; Lenglet, A; Perreault, S; Qazi, JZ | 1 |
| Chan, YH; Chao, TF; Chen, SW; Chen, WM; Kuo, CT; Lee, HF; Li, PR; Lip, GYH; See, LC; Yeh, YH | 1 |
| Brigida, M; Candelli, M; Gabrielli, M; Ojetti, V; Petruzziello, C; Saviano, A | 1 |
| Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H | 1 |
| Ansell, J; Freedman, D; Siegal, DM | 1 |
| Matre, NB; McLaughlin, EM; Naik, KD; Rozycki, AJ; Whitson, BA | 1 |
| Chai-Adisaksopha, C; Hantrakool, S; Hantrakun, N; Niprapan, P; Norasetthada, L; Piriyakhuntorn, P; Punnachet, T; Rattanathammethee, T; Rattarittamrong, E; Tantiworawit, A; Thiankhaw, K; Wongcharoen, W | 1 |
| Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H | 1 |
| Gao, JJ; Li, ZW; Wang, B; Xu, HW; Ye, HZ; Zhou, H | 1 |
| Aktan, A; Arslan, B; Aslan, B; Demir, M; Ertaş, F; Günlü, S; Güzel, T; Kılıç, R; Özbek, M | 1 |
| Ágústsson, AS; Björnsson, ES; Guðmundsdóttir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Önundarson, PT; Pálsson, DA; Reynisson, IE; Rumba, E | 1 |
| Björck, F; Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Ashton, V; Berger, JS; Bookhart, B; Boudreau, J; Germain, G; Laliberté, F; Lefebvre, P; Lejeune, D; Weir, MR | 1 |
| Bindler, RJ; Caverley, ZR; Mendelson, S; Soh, P | 1 |
| Chaiyakunapruk, N; Nathisuwan, S; Nelson, RE; Nonthasawadsri, T; Syeed, MS | 1 |
| Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
| Dilokthornsakul, P; Nimworapan, M; Niyomsri, S; Wongcharoen, W | 1 |
| Desai, NR; Dhruva, SS; Graham, DJ; Inselman, JW; Lee, JY; Ngufor, C; Noseworthy, PA; Polley, E; Ross, JS; Shah, ND; Siontis, KC; Yao, X | 1 |
| Bessette, LG; Bykov, K; Cervone, A; Kim, DH; Lin, KJ; Mastrorilli, JM; Singer, DE | 1 |
| Al Qaraghuli, F; Fiedler-Kelly, J; Gonzalez, D; Powell, JR; Weiner, D | 1 |
| Chan, EW; Li, X; Li, Y; Peng, K; Wong, ICK | 1 |
| Chen, X; Dai, H; Du, X; Gu, P; Guan, C; Huang, N; Huang, X; Li, R; Lin, X; Liu, X; Liu, Y; Lv, M; Wu, T; Xu, W; Zhang, J; Zhang, M; Zhang, W; Zheng, Q; Zhu, Z | 1 |
| Alves da Silva, P; Caldeira, D; Pinto, FJ | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Apolinario, M; Firth, C; Keddis, MT; Lim, ES; Shamoun, F; Zhang, N | 1 |
| Atreja, N; Bell, G; Cato, M; Cheng, D; DeKoven, M; Divino, V; Hernandez, I; Hines, DM; Hood, DW; Kariuki, W; Russ, C; Xie, L | 1 |
| Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J | 1 |
| Alt, E; Bessette, LG; Kim, DH; Mahesri, M; Najafzadeh, M; Schneeweiss, S; Shin, H; Wang, SV | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Arora, P; Ghanekar, S; Muehrcke, M; Russell, M | 1 |
| Yin, E | 1 |
| Chan, YH; Fong, KY; Lip, GYH; Tan, VH; Yeo, C | 1 |
| Gao, J; Miao, L; Shi, D; Shi, J; Song, L; Yu, H; Zhu, C | 1 |
| Akerman, M; Chin-Hon, J; Davenport, L; Hindenburg, A; Huang, J | 1 |
| Gu, ZC; Lin, HW; Liu, BL; Ma, EL; Pan, MM; Wang, J; Wang, X; Wu, B; Zhang, C | 1 |
| Chang, YM; Chen, CH; Hsieh, MT; Lin, PY; Lin, SH; Liu, CH; Sung, PS; Wang, CM | 1 |
288 review(s) available for dabigatran and warfarin
| Article | Year |
|---|---|
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Topics: Fibrinolytic Agents; Humans; Molecular Structure; Thrombosis | 2022 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
The new anticoagulants.
Topics: Anticoagulants; Antithrombin III; Benzimidazoles; Dabigatran; Humans; Oligosaccharides; Pyridines; Thrombin; Warfarin | 2007 |
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Cost-Benefit Analysis; Dabigatran; Humans; Platelet Aggregation Inhibitors; Pyridines; Stroke; Ticlopidine; Warfarin | 2010 |
Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Pyridines; Thrombin; Warfarin | 2009 |
[Current state and perspectives of pharmacological and non-pharmacological treatment of atrial fibrillation: overview].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Dabigatran; Drug Design; Fibrinolytic Agents; Humans; International Normalized Ratio; Pyridines; Warfarin | 2010 |
Old versus new anticoagulants: focus on pharmacology.
Topics: Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2010 |
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzimidazoles; Benzylamines; Contraindications; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2010 |
Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Male; Middle Aged; Pyridines; Stroke; Warfarin | 2010 |
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Biphenyl Compounds; Dabigatran; Humans; Irbesartan; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Warfarin | 2010 |
Stroke in atrial fibrillation--hope on the horizon?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Heart Atria; Humans; Prostheses and Implants; Stroke; Warfarin | 2010 |
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Stroke; Thrombin; Venous Thromboembolism; Warfarin | 2011 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Health Status Indicators; Humans; Risk Assessment; Stroke; Vitamin K; Warfarin | 2011 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin | 2010 |
Atrial fibrillation in 2010: advances in treatment and management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
[Dabigatran, a new oral anticoagulant].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
New options for stroke prevention in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2010 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke; Warfarin | 2011 |
[Pharmacological and clinical profiles of the direct thrombin inhibitor dabigatran etexilate methane sulfate (Prazaxa(®)) ].
Topics: Animals; Antithrombins; Benzimidazoles; Dabigatran; Haplorhini; Humans; Pyridines; Rats; Stroke; Thrombosis; Warfarin | 2011 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Catheterization; Cardiac Surgical Procedures; Dabigatran; Humans; Preventive Health Services; Stroke; Treatment Outcome; Warfarin | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echocardiography, Three-Dimensional; Electric Countershock; Humans; International Normalized Ratio; Premedication; Randomized Controlled Trials as Topic; Risk Adjustment; Thromboembolism; Time Factors; Warfarin | 2011 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Enoxaparin; Humans; Pyridines; Venous Thromboembolism; Warfarin | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Evidence-Based Medicine; Hemorrhage; Humans; Italy; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmaceutics; Blood Coagulation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Approval; Drug Dosage Calculations; Drug Monitoring; Humans; Risk Assessment; Therapeutic Equivalency; Thrombin; Thromboembolism; Warfarin | 2011 |
Should dabigatran replace warfarin for stroke prevention in AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Stroke; Warfarin | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
Promise of factor Xa inhibition in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors; Stroke; United States; Warfarin | 2012 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemodynamics; Hemorrhage; Humans; Risk Factors; Stroke; Therapeutic Equivalency; Treatment Outcome; Ventricular Dysfunction, Left; Warfarin | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Decision Making; Factor Xa Inhibitors; Humans; Risk Factors; Stroke; Thrombin; Vitamin K; Warfarin | 2012 |
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Venous Thromboembolism; Warfarin | 2011 |
[Interpretation of hemostatic and fibrinolytic markers].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Dabigatran; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemostasis; Humans; Partial Thromboplastin Time; Plasminogen Activators; Prothrombin Time; Thrombomodulin; Warfarin | 2011 |
Using anticoagulants to steer clear of clots.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Heparin; Humans; Thrombosis; Warfarin | 2012 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Warfarin versus dabigatran: comparing the old with the new.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Warfarin | 2012 |
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Male; Stroke; Warfarin | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Thrombosis; Warfarin | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Liver; Myocardial Infarction; Warfarin | 2012 |
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Stroke; Warfarin | 2012 |
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Stroke; Thromboembolism; Warfarin | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran and left atrial appendage thrombus.
Topics: Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Diseases; Humans; Middle Aged; Thrombosis; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
Anticoagulant therapy: basic principles, classic approaches and recent developments.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet Aggregation Inhibitors; Thrombin; Thromboembolism; Thrombophilia; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Embolism; Humans; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Complications of anticoagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination; Drug Monitoring; Food-Drug Interactions; Hemorrhage; Heparin; Humans; Hypersensitivity; Injections, Subcutaneous; Necrosis; Osteoporosis; Skin Diseases; Subcutaneous Tissue; Thrombocytopenia; Warfarin | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
Dabigatran in clinical practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Humans; International Normalized Ratio; Pyridines; Stroke; Thromboembolism; Warfarin | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coumarins; Dabigatran; Female; Hematology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Sex Factors; Warfarin | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Topics: Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Postoperative Hemorrhage; Pyridines; Surgery, Oral; Tooth Extraction; Warfarin | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Odds Ratio; Pyridines; Risk Factors; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Chi-Square Distribution; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Odds Ratio; Pyridines; Risk Factors; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Warfarin | 2013 |
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Perioperative Care; Stroke; Warfarin | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Warfarin | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Myocardial Infarction; Odds Ratio; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Stroke; Venous Thromboembolism; Warfarin | 2013 |
A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Pharmaceutical; Gastrointestinal Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2014 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Management of anticoagulation around pacemaker and defibrillator surgery.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Defibrillators, Implantable; Humans; Intracranial Embolism; Male; Pacemaker, Artificial; Warfarin | 2014 |
Protocol in managing oral surgical patients taking dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Female; Humans; Male; Oral Surgical Procedures; Tooth Extraction; Warfarin; Withholding Treatment | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Does dabigatran interfere with intraablation heparinization?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Heparin; Humans; Risk Factors; Stroke; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Warfarin | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
[Progress of anticoagulation therapy in atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Stroke; Treatment Outcome; Warfarin | 2015 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Contraindications; Dabigatran; Humans; Medication Adherence; Models, Cardiovascular; Pyridines; Warfarin | 2015 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Target-specific oral anticoagulants and the hospitalist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2015 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
New oral anti-coagulants: Implications for neurosurgery.
Topics: Animals; Anticoagulants; Dabigatran; Hemorrhage; Humans; Neurosurgery; Pyrazoles; Pyridones; Warfarin | 2015 |
Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dental Care for Chronically Ill; Factor Xa Inhibitors; Humans; Oral Hemorrhage; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Rivaroxaban; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Humans; Perioperative Care; Randomized Controlled Trials as Topic; Treatment Outcome; Warfarin | 2015 |
Oral anticoagulants and risk of nephropathy.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Anticoagulants; Dabigatran; Disease Models, Animal; Humans; Rats; Renal Insufficiency, Chronic; Risk Factors; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Management of anticoagulation in patients with acute gastrointestinal bleeding.
Topics: Acenocoumarol; Acute Disease; Algorithms; Anticoagulants; Coagulants; Dabigatran; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K; Warfarin | 2015 |
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinations; Factor Xa Inhibitors; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Stents; Thrombosis; Ticlopidine; Warfarin | 2015 |
The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?
Topics: Animals; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Pyrazoles; Pyridones; Warfarin | 2015 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Defibrillators, Implantable; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Warfarin | 2016 |
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Prothrombin; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2016 |
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Renal Insufficiency, Chronic; Stroke; Warfarin | 2016 |
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Rivaroxaban; Warfarin | 2016 |
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Why switch from warfarin to NOACs?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Vitamin K; Warfarin | 2016 |
[Companion Diagnostics for Thrombotic Disease].
Topics: Administration, Oral; Anticoagulants; Cytochrome P-450 CYP2C9; Dabigatran; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Thrombosis; Vitamin K Epoxide Reductases; Warfarin | 2015 |
The discovery of dabigatran etexilate for the treatment of venous thrombosis.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Disease Models, Animal; Drug Interactions; Humans; Venous Thromboembolism; Warfarin | 2016 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Minimizing the Risk of Bleeding with NOACs in the Elderly.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Precision Medicine; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Coagulation disorders in the intensive care unit - what is new?].
Topics: Anticoagulants; Dabigatran; Hemophilia A; Hemorrhage; Heparin; Humans; Intensive Care Units; Rivaroxaban; Thrombocytopenia; Thrombosis; Warfarin | 2016 |
Drug Treatment of Venous Thromboembolism in the Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2016 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Anticoagulation for patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin | 2016 |
[Cerebral infarction and transient ischemic attack].
Topics: Acute-Phase Reaction; Anticoagulants; Cerebral Infarction; Dabigatran; Endovascular Procedures; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Japan; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Recombinant Proteins; Recurrence; Rivaroxaban; Tissue Plasminogen Activator; Warfarin | 2016 |
Dabigatran in clinical practice: Contemporary overview of the evidence.
Topics: Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Stroke; Venous Thromboembolism; Warfarin | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
A systematic review of anti-thrombotic therapy in epistaxis.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epistaxis; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Ticlopidine; Tranexamic Acid; Warfarin | 2016 |
Do novel anticoagulant agents increase the risk of perioperative complications during implantable cardiac rhythm device insertion?
Topics: Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Dabigatran; Defibrillators, Implantable; Humans; Intraoperative Complications; Male; Pacemaker, Artificial; Postoperative Complications; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hemostasis, Surgical; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
A Review of the Clinical Subgroup Analyses From the RE-LY Trial.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Current Perspective on Use of NOAC in Clinical Practice in India.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; India; Pyrazoles; Stroke; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2016 |
Management of bleeding in patients receiving non-vitamin K antagonists.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Treatment Outcome; Warfarin | 2017 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Warfarin | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Intracranial Embolism; Intracranial Thrombosis; Rivaroxaban; Stroke; Warfarin | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Risk Factors; Warfarin | 2017 |
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Geriatrics; Hemorrhage; Humans; Metabolic Clearance Rate; Renal Insufficiency, Chronic; Warfarin | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Consensus; Dabigatran; Delphi Technique; Europe; Evidence-Based Practice; Female; Humans; Long-Term Care; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Stroke; Thiazoles; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Clinical Trials as Topic; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Markov Chains; Middle Aged; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk; Thiazoles; Warfarin | 2017 |
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Myocardial Infarction; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Reversal agents for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Incidence of Visible Hematuria Among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients.
Topics: Age Factors; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematuria; Humans; Incidence; Male; Patient Safety; Prognosis; Risk Assessment; Rivaroxaban; Sex Factors; Warfarin | 2018 |
The role of direct oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Female; Humans; Incidence; Male; Prognosis; Pyridines; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Novel oral anticoagulants in the preoperative period: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Preoperative Period; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Heart Transplantation; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2018 |
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Warfarin | 2019 |
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Cerebral Infarction; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Postoperative Hemorrhage; Risk Factors; Rivaroxaban; Severity of Illness Index; Thromboembolism; Warfarin | 2018 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin | 2018 |
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Thiazoles; Thromboembolism; Warfarin | 2018 |
Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; Warfarin | 2019 |
Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2019 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Antacids; Anticoagulants; Case-Control Studies; Cohort Studies; Coumarins; Dabigatran; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Male; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2020 |
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Care Bundles; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2020 |
Barriers and facilitators to optimal oral anticoagulant management: a scoping review.
Topics: Anticoagulants; Dabigatran; Disease Management; Factor Xa Inhibitors; Humans; Quality of Health Care; Rivaroxaban; Thromboembolism; Vitamin K; Warfarin | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Humans; Japan; Rivaroxaban; Stroke; Warfarin | 2020 |
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Consensus Development Conferences as Topic; Dabigatran; Europe; Female; Humans; Long-Term Care; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Periprocedural Management of Oral Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Surgical Procedures, Operative; Warfarin | 2020 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Network Meta-Analysis; Pyridones; Rivaroxaban; Stroke; Warfarin | 2020 |
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Topics: Anticoagulants; Blood Pressure; Dabigatran; Humans; Thrombin; Warfarin | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - A systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2021 |
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Observational Studies as Topic; Pyridones; Risk Assessment; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2021 |
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; Venous Thromboembolism; Warfarin | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Rivaroxaban; Stroke; Warfarin | 2021 |
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity, Morbid; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Ticagrelor; Warfarin | 2022 |
Anticoagulant-related nephropathy: Focus on novel agents. A review.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Drug Interactions Affecting Oral Anticoagulant Use.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Hemorrhage; Humans; Pyridones; Rivaroxaban; Warfarin | 2022 |
Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Neoplasms; Network Meta-Analysis; Stroke; Treatment Outcome; Warfarin | 2022 |
The association of non-vitamin K antagonist oral anticoagulants
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Osteoporotic Fractures; Rivaroxaban; Stroke; Warfarin | 2023 |
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Dialysis; Rivaroxaban; Stroke; Warfarin | 2022 |
Acute Pulmonary Embolism: A Review.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dabigatran; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Pulmonary Embolism; Risk; Rivaroxaban; United States; Vitamin K; Warfarin | 2022 |
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Network Meta-Analysis; Rivaroxaban; Venous Thromboembolism; Warfarin | 2022 |
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2022 |
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2023 |
Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Warfarin | 2022 |
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
The Risk of Postpolypectomy Bleeding in Patients Receiving Direct Oral Anticoagulants compared to Warfarin or Nonanticoagulation: A Systematic Review with Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Retrospective Studies; Warfarin | 2022 |
Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thailand; Venous Thromboembolism; Warfarin | 2023 |
Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2023 |
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Pyridones; Rheumatic Heart Disease; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2023 |
Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2023 |
Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Venous Thromboembolism; Warfarin | 2023 |
108 trial(s) available for dabigatran and warfarin
| Article | Year |
|---|---|
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; International Normalized Ratio; Liver Function Tests; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Pyridines; Thromboembolism; Warfarin | 2007 |
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Transesophageal; Electric Countershock; Follow-Up Studies; Humans; Intracranial Thrombosis; Prospective Studies; Pyridines; Research Design; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Dyspepsia; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Liver; Male; Middle Aged; Myocardial Infarction; Prodrugs; Proportional Hazards Models; Pyridines; Stroke; Warfarin | 2009 |
[Dabigatran versus Warfarin in patients with atrial fibrillation. Results of the RE-LY study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Prodrugs; Pyridines; Single-Blind Method; Stroke; Time Factors; Treatment Outcome; Warfarin | 2009 |
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Female; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2009 |
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Treatment Outcome; Warfarin | 2010 |
[Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study].
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Middle Aged; Pyridines; Survival Rate; Treatment Outcome; Venous Thromboembolism; Warfarin | 2010 |
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Longitudinal Studies; Male; Pyridines; Stroke; Treatment Outcome; Warfarin | 2010 |
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyridines; Risk Factors; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Electric Stimulation Therapy; Hemorrhage; Humans; Incidence; Retrospective Studies; Stroke; Warfarin | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Stroke; Warfarin | 2011 |
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Follow-Up Studies; Humans; Prospective Studies; Pyridines; Risk Factors; Stroke; Vitamin K; Warfarin | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Factors; Time Factors; Warfarin | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Warfarin | 2011 |
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Heart Arrest; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Single-Blind Method; Warfarin | 2012 |
[Expectation to and problems of thrombin inhibitor].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Radiography; Risk Factors; Warfarin | 2012 |
[Series: Clinical study from Japan and its reflections RE-LY trial].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Humans; International Cooperation; Male; Pyridines; Warfarin | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain Ischemia; Cardiac Pacing, Artificial; Cataract Extraction; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Risk Factors; Stroke; Thromboembolism; Warfarin | 2012 |
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Female; Heart Valve Prosthesis Implantation; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Research Design; Thromboembolism; Warfarin; Young Adult | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Life Expectancy; Quality-Adjusted Life Years; Stroke; Sweden; Warfarin | 2013 |
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Thromboembolism; Warfarin | 2012 |
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Premedication; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Thrombin; Warfarin | 2013 |
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2013 |
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Prospective Studies; Quality of Life; Warfarin | 2013 |
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome; United States; Warfarin | 2013 |
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Benzimidazoles; Brain Ischemia; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyridines; Stroke; Warfarin | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2013 |
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Warfarin | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Stroke; Thromboembolism; Warfarin | 2013 |
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Warfarin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Choice Behavior; Dabigatran; Decision Support Techniques; Female; Humans; Male; Middle Aged; Warfarin | 2013 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrhage; Humans; Software; Thromboembolism; Warfarin | 2014 |
Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Stroke; Turkey; Warfarin | 2016 |
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Dabigatran; Female; Hemoglobins; Humans; Incidence; Male; Middle Aged; Pacemaker, Artificial; Postoperative Hemorrhage; Prospective Studies; Warfarin | 2014 |
Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Thrombosis; Treatment Outcome; Ultrasonography; Warfarin | 2015 |
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridines; Risk Factors; Single-Blind Method; Warfarin | 2015 |
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Diabetes Mellitus; Drug Evaluation; Female; Humans; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2015 |
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Topics: Aged; Asian People; Creatinine; Dabigatran; Embolism; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Stroke; Warfarin | 2015 |
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Stroke; Treatment Outcome; Warfarin | 2015 |
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Double-Blind Method; Female; Health Services; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Pulmonary Embolism; Quality-Adjusted Life Years; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2016 |
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
Topics: Aged; Anticoagulants; Antithrombins; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Risk; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Dabigatran etexilate and reduction in serum apolipoprotein B.
Topics: Aged; Aged, 80 and over; Anticoagulants; Apolipoprotein A-I; Apolipoprotein B-100; Biomarkers; Blood Coagulation; Dabigatran; Down-Regulation; Drug Administration Schedule; Female; Humans; International Normalized Ratio; Lipid Metabolism; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Warfarin | 2016 |
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Monitoring; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Dabigatran; Female; Hemorrhage; Humans; Interleukin-6; Male; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Stroke; Thromboembolism; Warfarin | 2015 |
Ablation perioperative dabigatran in use envisioning in Japan: The ABRIDGE-J Study Design.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Thromboembolism; Warfarin | 2016 |
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor VIIa; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prognosis; Risk Factors; Stroke; Warfarin | 2016 |
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.
Topics: Adolescent; Adult; Antithrombins; Atrial Fibrillation; Bioprosthesis; Cardiac Valve Annuloplasty; Dabigatran; Female; Heart Diseases; Humans; Male; Middle Aged; Pilot Projects; Thrombosis; Treatment Outcome; Warfarin; Young Adult | 2016 |
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Disease Management; Female; Hemorrhage; Humans; Male; Warfarin | 2016 |
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Topics: Administration, Oral; Anticoagulants; Arrhythmias, Cardiac; Canada; Cause of Death; Dabigatran; Defibrillators, Implantable; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Pacemaker, Artificial; Practice Guidelines as Topic; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2016 |
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
Topics: Adult; Aged; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2016 |
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Data Interpretation, Statistical; Decision Making; Female; Hemorrhage; Humans; Male; Models, Statistical; Regression Analysis; Risk Factors; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Venous Thromboembolism; Warfarin; Young Adult | 2016 |
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Administration Schedule; Female; Heart Valve Diseases; Humans; Male; Prospective Studies; Retrospective Studies; Time Factors; Warfarin | 2016 |
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Protocols; Coronary Artery Disease; Coronary Thrombosis; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome; Warfarin | 2016 |
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemoprevention; Dabigatran; Embolism; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Prevalence; Prospective Studies; Stroke; Warfarin | 2017 |
[Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY].
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Prospective Studies; Stroke; Warfarin | 2016 |
[The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Postoperative Complications; Stroke; Warfarin | 2017 |
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Defibrillators, Implantable; Drug Administration Schedule; Drug Substitution; Female; Hematoma; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pacemaker, Artificial; Prosthesis Implantation; Thrombosis; Time Factors; Treatment Outcome; Warfarin | 2017 |
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Risk Factors; Stroke; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling; Warfarin | 2018 |
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Stroke; Time Factors; Warfarin | 2018 |
Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2018 |
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Internationality; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Warfarin | 2018 |
Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Cerebral Veins; Clinical Trials, Phase III as Topic; Dabigatran; Dura Mater; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Venous Thrombosis; Warfarin; Young Adult | 2018 |
Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pacemaker, Artificial; Pilot Projects; Prospective Studies; Prosthesis Implantation; Pyrazoles; Pyridones; Rivaroxaban; Single-Blind Method; Warfarin | 2018 |
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; Norway; Pharmacoepidemiology; Risk Factors; Rivaroxaban; Thrombosis; Warfarin | 2018 |
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Thrombosis; Treatment Outcome; Warfarin | 2019 |
Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study.
Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Catheter Ablation; Comorbidity; Dabigatran; Europe; Female; Humans; Male; Middle Aged; North America; Prospective Studies; Warfarin | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Endpoint Determination; Female; Hospitalization; Humans; Male; Risk; Warfarin | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cognition; Cognitive Dysfunction; Dabigatran; Dementia; Female; Humans; Incidence; International Normalized Ratio; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2019 |
Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Heparin; Humans; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Warfarin | 2019 |
Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Perioperative Period; Prospective Studies; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intracranial Thrombosis; Male; Middle Aged; Prospective Studies; Single-Blind Method; Treatment Outcome; Venous Thrombosis; Warfarin | 2019 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Prospective Studies; Proton Pump Inhibitors; Warfarin | 2020 |
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme 2; Antithrombins; Atrial Fibrillation; Betacoronavirus; Biomarkers; Cohort Studies; Coronavirus Infections; COVID-19; Dabigatran; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Stroke; Warfarin | 2020 |
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Atrial Fibrillation; Dabigatran; Humans; Italy; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.
Topics: Anticoagulants; Cerebral Veins; Dabigatran; Humans; Prospective Studies; Sinus Thrombosis, Intracranial; Stroke; Treatment Outcome; Venous Thrombosis; Warfarin | 2022 |
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
Topics: Aspirin; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome; Warfarin | 2021 |
Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; China; Dabigatran; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Heparin; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2021 |
Assessment of the Potential for Veverimer Drug-Drug Interactions.
Topics: Absorption, Physicochemical; Acidosis; Administration, Oral; Adolescent; Adult; Aspirin; Cross-Over Studies; Dabigatran; Drug Interactions; Ethacrynic Acid; Female; Furosemide; Gastrointestinal Absorption; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Polymers; Polypharmacy; Renal Insufficiency, Chronic; Solubility; Warfarin; Young Adult | 2021 |
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Topics: Anticoagulants; Cross-Sectional Studies; Dabigatran; Follow-Up Studies; Humans; Postthrombotic Syndrome; Quality of Life; Venous Thromboembolism; Warfarin | 2021 |
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Time Factors; Warfarin | 2021 |
Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Heart Valve Diseases; Humans; Stroke; Treatment Outcome; Warfarin | 2022 |
Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brazil; Cognition; Dabigatran; Humans; Stroke; Warfarin | 2022 |
Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.
Topics: Accidental Falls; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Retrospective Studies; Stroke; Warfarin | 2023 |
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Stroke; Treatment Outcome; United States; Warfarin | 2023 |
723 other study(ies) available for dabigatran and warfarin
| Article | Year |
|---|---|
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
Can we rely on RE-LY?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Warfarin | 2009 |
At last, a RE-LYable alternative to warfarin for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dyspepsia; Hemorrhage; Humans; Multicenter Studies as Topic; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Warfarin | 2009 |
[The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Warfarin | 2009 |
Atrial fibrillation: A promising new anticoagulant for stroke prevention.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Intracranial Hemorrhages; Pyridines; Risk Factors; Stroke; Warfarin | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Warfarin | 2009 |
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Patient Dropouts; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Ireland; Pyridines; Stroke; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Hemorrhage; Humans; Incidence; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2009 |
Dabigatran versus warfarin for venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Drug Monitoring; Humans; Pyridines; Venous Thromboembolism; Warfarin | 2010 |
Dabigatran versus warfarin for venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Drug Costs; Humans; International Normalized Ratio; Pyridines; Venous Thromboembolism; Warfarin | 2010 |
Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Europe; Hemorrhage; Humans; Middle Aged; Multicenter Studies as Topic; North America; Pyridines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Venous Thromboembolism; Warfarin | 2010 |
When a virtue becomes a problem. The new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Medication Adherence; Risk; Vitamin K; Warfarin | 2010 |
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin | 2010 |
Quality of anticoagulation control in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Multicenter Studies as Topic; Pyridines; Quality of Health Care; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Dabigatran v warfarin. Compare with higher standard.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2010 |
First oral warfarin alternative approved in the US.
Topics: Animals; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Discovery; Humans; Prodrugs; Pyridines; United States; Warfarin | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Stroke; Warfarin | 2011 |
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Topics: Administration, Oral; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Vitamin K; Warfarin | 2010 |
Warfarin: is the end nigh? Please?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2010 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin | 2010 |
Warfarin versus new agents: interpreting the data.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Enzyme Inhibitors; Humans; Pyridines; Thrombin; Warfarin | 2010 |
The difference between Tdap and DTaP; dabigatran versus warfarin.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diphtheria-Tetanus-acellular Pertussis Vaccines; Humans; Product Surveillance, Postmarketing; Warfarin | 2011 |
Anticoagulation: improve care quality or use new alternatives?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pharmaceutical Services; Pharmacogenetics; Pyridines; Quality Assurance, Health Care; Stroke; Warfarin | 2011 |
Next generation anticoagulants may push warfarin to the wayside.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Evaluation; Humans; Medication Adherence; Stroke; Warfarin | 2011 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; Canada; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Embolism, Air; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin | 2011 |
New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug and Narcotic Control; Drug Approval; Humans; United States; United States Food and Drug Administration; Warfarin | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Decision Trees; Hemorrhage; Humans; Markov Chains; Risk Factors; Stroke; Warfarin | 2011 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Humans; Male; Recurrence; Stroke; Ultrasonography; Warfarin | 2012 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Patient Education as Topic; Warfarin | 2011 |
Dabigatran-induced rash.
Topics: Aged; Anticoagulants; Benzimidazoles; Dabigatran; Drug Eruptions; Humans; Male; Medication Errors; Pruritus; Pyridines; Warfarin | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Embolism; Humans; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Cerebral Hemorrhage; Collagenases; Dabigatran; Hematoma; Injections; Male; Mice; Mice, Inbred Strains; Microscopy, Fluorescence; Partial Thromboplastin Time; Pyridines; Time Factors; Warfarin | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Stroke; Warfarin | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Tolerance; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Dabigatran: will it change clinical practice?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin | 2011 |
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Life Expectancy; Male; Models, Cardiovascular; Pyridines; Quality of Life; Risk Assessment; Treatment Outcome; United Kingdom; Warfarin | 2011 |
Cost of dabigatran for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Humans; Male; Pyridines; Warfarin | 2011 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Stroke; Warfarin | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Evidence-Based Medicine; Humans; International Normalized Ratio; Pakistan; Pyridines; Stroke; Treatment Outcome; Warfarin | 2011 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Thrombin; Warfarin | 2012 |
Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Registries; Warfarin | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Feasibility Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Registries; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Markov Chains; Models, Statistical; Monte Carlo Method; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2012 |
Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Denmark; Female; Humans; Male; Models, Theoretical; Myocardial Infarction; Pyridines; Risk Assessment; Stroke; Warfarin | 2012 |
Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Drug Eruptions; Drug Substitution; Female; Humans; Necrosis; Protein C Deficiency; Pyridines; Severity of Illness Index; Skin; Warfarin; Young Adult | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Mice; Mice, Inbred C57BL; Stroke; Tissue Plasminogen Activator; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Hemorrhage; Humans; Patient Selection; Stroke; Warfarin | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Female; Heart Valve Prosthesis; Hemorrhage; Male; Mitral Valve; Models, Animal; Sus scrofa; Thrombosis; Warfarin | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
An anticoagulation option for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Humans; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Stroke; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Prospective Studies; Stroke; Thromboembolism; Warfarin | 2012 |
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2012 |
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Genotype; Humans; Stroke; Warfarin | 2012 |
Dabigatran: uncharted waters and potential harms.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pharmacovigilance; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Warfarin | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Warfarin | 2013 |
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.
Topics: Animals; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Blood Coagulation Disorders; Dabigatran; Mice; Prothrombin; Pyridines; Warfarin | 2012 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility Determination; Fees, Pharmaceutical; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Patient Preference; Patient Selection; Practice Patterns, Physicians'; Surveys and Questionnaires; United States; Warfarin | 2013 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Dabigatran: rational dose individualisation and monitoring guidance is needed.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; New Zealand; Warfarin | 2012 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Stroke; Treatment Outcome; Warfarin | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Evaluating and assessing dabigatran drug interactions.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Consultants; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Monitoring; Female; Humans; International Normalized Ratio; Middle Aged; Pharmaceutical Services; Pharmacists; Professional Role; Warfarin | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Costs; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Guideline Adherence; Health Care Surveys; Health Expenditures; Humans; Medical Audit; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Preventive Health Services; Thromboembolism; Time Factors; United States; Warfarin | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2011 |
Dabigatran (Pradaxa). An alternative to warfarin (Coumadin) is approved to help treat patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Warfarin | 2011 |
Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Female; Heparin; Humans; Linear Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Risk Factors; Treatment Outcome; Warfarin | 2012 |
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Europe; Humans; Postoperative Complications; Practice Guidelines as Topic; United States; Vascular Surgical Procedures; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kong; Humans; Male; Quality of Life; Retrospective Studies; Stroke; Warfarin | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Dabigatran: beyond the RE-LY study].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Venous Thromboembolism; Warfarin | 2012 |
[Scope of the latest RE-LY substudies: clinical implications].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
[Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Thromboembolism; Warfarin | 2012 |
Risky anticoagulants: meds have the potential to turn minor trauma into a major disaster.
Topics: Accidental Falls; Aged; Anticoagulants; Benzimidazoles; Dabigatran; Fatal Outcome; Female; Heparin; Humans; Pyridines; Subarachnoid Hemorrhage, Traumatic; Tomography, X-Ray Computed; Trauma Centers; Warfarin | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Catheter Ablation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electrocardiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Predictive Value of Tests; Preoperative Care; Reference Values; Risk Assessment; Severity of Illness Index; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Female; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Stroke; Warfarin | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Rivaroxaban; Warfarin | 2012 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Extended treatment of venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2013 |
Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Platelet Aggregation Inhibitors; Telangiectasia, Hereditary Hemorrhagic; Warfarin | 2013 |
Dabigatran "non-inferior" to warfarin, but only just.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Pulmonary Embolism; Treatment Outcome; Venous Thrombosis; Warfarin | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Antidotes edge closer to reversing effects of new blood thinners.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Humans; Pyrazoles; Pyridones; Recombinant Proteins; Vitamin K; Warfarin | 2013 |
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2013 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Drug Utilization Review; Female; Health Expenditures; Hong Kong; Hospital Costs; Hospitals, Teaching; Humans; Male; Middle Aged; Preventive Health Services; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Eruptions; Eosinophilia; Exanthema; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Prospective Studies; Stroke; Warfarin | 2013 |
An audit of dabigatran etexilate prescribing in Victoria.
Topics: Aged; Anticoagulants; Benzimidazoles; Dabigatran; Drug Prescriptions; Humans; Medical Audit; Pyridines; Retrospective Studies; Victoria; Warfarin | 2013 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Female; Humans; International Normalized Ratio; Male; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; South Africa; Stroke; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Intraoperative Care; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Perioperative Care; Postoperative Complications; Prospective Studies; Registries; Risk Assessment; Severity of Illness Index; Survival Rate; Thromboembolism; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2013 |
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Denmark; Dose-Response Relationship, Drug; Drug Prescriptions; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hospitalization; Humans; Incidence; Intracranial Hemorrhages; Logistic Models; Male; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Prospective Studies; Pulmonary Embolism; Pyridines; Registries; Stroke; Warfarin | 2013 |
Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Dabigatran; Dose-Response Relationship, Drug; Female; Heparin; Humans; Male; Middle Aged; Pyridines; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Warfarin | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Research Design; Stroke; Warfarin | 2013 |
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Computer Simulation; Dabigatran; Decision Support Techniques; Decision Trees; Female; France; Health Services Research; Humans; Incidence; Male; Models, Statistical; Multivariate Analysis; Outcome and Process Assessment, Health Care; Prevalence; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood-Brain Barrier; Cerebral Arteries; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Humans; Ischemia; Mice; Mice, Inbred C57BL; Rats; Stroke; Thrombolytic Therapy; Warfarin | 2013 |
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Health Care Costs; Humans; Models, Economic; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin | 2013 |
Dabigatran bleed risk with closed head injuries: are we prepared?
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage, Traumatic; Clinical Protocols; Craniocerebral Trauma; Dabigatran; Female; Humans; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Warfarin; Young Adult | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Substitution; Female; Humans; Male; Referral and Consultation; Stroke; United States; Warfarin | 2013 |
Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Warfarin | 2013 |
Anticoagulant guidelines.
Topics: Anticoagulants; Benzimidazoles; Coumarins; Dabigatran; Dental Care for Chronically Ill; Hemostatic Techniques; Humans; Interprofessional Relations; Morpholines; Oral Hemorrhage; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2013 |
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Echocardiography; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitral Valve Stenosis; Rheumatic Heart Disease; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coronary Occlusion; Cost-Benefit Analysis; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Markov Chains; Models, Statistical; Ontario; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Risk Factors; Stroke; Warfarin | 2013 |
Placing a value on new technologies.
Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Male; Percutaneous Coronary Intervention; Stroke; Transplantation; Warfarin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Postoperative Complications; Thrombosis; Warfarin | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
RE-LYing on dabigatran for periprocedural anticoagulation: is it safe?
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Embolism; Intracranial Thrombosis; Male; Warfarin | 2013 |
[New anticoagulants, new emergencies?].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Warfarin | 2013 |
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Device Removal; Drug Administration Schedule; Electric Countershock; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Prosthesis Implantation; Reoperation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Anticoagulation-associated upper gastrointestinal haemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Medical Audit; Upper Gastrointestinal Tract; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Contrast Media; Dabigatran; Iopamidol; Male; Mice; Radiography, Dual-Energy Scanned Projection; Time Factors; Warfarin | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Incidence; Intracranial Embolism; Intracranial Thrombosis; Japan; Male; Middle Aged; Premedication; Prospective Studies; Risk Factors; Treatment Outcome; Warfarin | 2013 |
New oral anticoagulants in heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure; Humans; Male; Stroke; Warfarin | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assessment; Stroke; Thrombosis; Warfarin | 2013 |
Dabigatran and mechanical heart valves--not as easy as we hoped.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Hemorrhage; Kidney; Kidney Glomerulus; Male; Rats; Rats, Sprague-Dawley; Warfarin | 2014 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Acute kidney injury: renal hazards of anticoagulant therapy.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Rats; Warfarin | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Female; Half-Life; Hemorrhage; Humans; Kidney Diseases; Male; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Warfarin | 2013 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, Animal; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Warfarin | 2014 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Diabetes Mellitus; Drug Therapy, Combination; Factor IX; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Risk Assessment; Risk Factors; Smoking; Vitamin K; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Stroke; Survival Analysis; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Warfarin | 2014 |
Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Cross-Sectional Studies; Dabigatran; Drug Prescriptions; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prodrugs; Pyridines; United States; Warfarin; Young Adult | 2014 |
A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/+) mice.
Topics: Age Factors; Animals; Benzimidazoles; Clopidogrel; Dabigatran; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Genes, APC; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrazoles; Pyridines; Pyridones; Risk Factors; Ticlopidine; Warfarin | 2014 |
Adherence, persistence, and switching patterns of dabigatran etexilate.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Databases, Pharmaceutical; Drug Substitution; Factor Xa Inhibitors; Humans; Medicare Part D; Medication Adherence; Pyridines; Retrospective Studies; United States; Warfarin | 2013 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Warfarin | 2014 |
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Brain; Brain Injuries; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Mice; Mice, Inbred C57BL; Warfarin | 2014 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Markov Chains; Pyridines; Stroke; Taiwan; Warfarin | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; United States; United States Food and Drug Administration; Warfarin | 2014 |
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Budgets; Cardiac Catheterization; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Germany; Humans; Models, Economic; Pyridines; Stroke; Time Factors; Treatment Outcome; Warfarin | 2014 |
Lessons from the RE-ALIGN trial.
Topics: Aged; Anticoagulants; Benzimidazoles; Bioprosthesis; Clinical Trials, Phase II as Topic; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial Infarction; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Thromboembolism; Warfarin | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
A new class of powerful and informative simultaneous confidence intervals.
Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biostatistics; Confidence Intervals; Dabigatran; Data Interpretation, Statistical; Humans; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospital Mortality; Humans; Intracranial Hemorrhages; Male; Odds Ratio; Retrospective Studies; Warfarin | 2014 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Insurance Claim Review; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk; Stroke; United States; Warfarin | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Dabigatran, bleeding, and the regulators.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Europe; Hemorrhage; Humans; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 2014 |
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2015 |
Haemostasis. Part 2: Medications that affect haemostasis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Hematologic Agents; Hemostasis, Surgical; Heparin; Humans; International Normalized Ratio; Oral Hemorrhage; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; Warfarin | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Substitution; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; International Normalized Ratio; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Stroke; United States; United States Department of Veterans Affairs; Warfarin | 2014 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Denmark; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Registries; Secondary Prevention; Stroke; Treatment Outcome; Warfarin | 2014 |
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Surgical Procedures; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Equipment Design; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Models, Statistical; Probability; Quality-Adjusted Life Years; Stroke; Treatment Outcome; Uncertainty; Warfarin | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Humans; Thromboplastin; Warfarin | 2015 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
[Thrombosis of a mechanical prosthetic mitral valve during dabigatran treatment].
Topics: Aged; Anticoagulants; Antithrombins; Dabigatran; Echocardiography, Transesophageal; Heart Valve Prosthesis; Humans; Male; Mitral Valve; Shock, Cardiogenic; Thrombosis; Warfarin | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk; United States; Warfarin | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; China; Cohort Studies; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Time Factors; Warfarin | 2015 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Perioperative Care; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Warfarin | 2015 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Heparin; Humans; Lower Extremity; Male; Middle Aged; Severity of Illness Index; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Warfarin | 2014 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Warfarin | 2014 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Humans; Ischemic Attack, Transient; Male; Middle Aged; Necrosis; Skin; Skin Diseases; Thrombosis; Warfarin | 2014 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Patterns of oral anticoagulants use in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Drug Substitution; Drug Utilization Review; Female; Hospitals, University; Humans; Male; Practice Patterns, Physicians'; Quebec; Retrospective Studies; Stroke; Time Factors; Treatment Outcome; Warfarin | 2015 |
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Defibrillators, Implantable; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Rivaroxaban; Thromboembolism; Warfarin | 2015 |
Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.
Topics: Aged; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Warfarin | 2015 |
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Germany; Humans; Pyrazoles; Pyridines; Pyridones; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Myocardial Infarction; Propensity Score; Retrospective Studies; Stroke; United States; Warfarin | 2015 |
Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Factors; Warfarin | 2015 |
Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kidney; Male; Middle Aged; Odds Ratio; United States; United States Food and Drug Administration; Warfarin | 2015 |
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2015 |
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Brain; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Hematoma; Mice; Thrombin Time; Warfarin | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population.
Topics: Aged; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2016 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Treatment Outcome; Warfarin | 2015 |
Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Causality; Cohort Studies; Comorbidity; Dabigatran; Denmark; Female; Fibrinolytic Agents; Gastrointestinal Diseases; Humans; Incidence; Male; Risk Factors; Survival Rate; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thromboembolism; Warfarin | 2015 |
Dabigatran vs. warfarin; is it time to change?
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Warfarin | 2015 |
Matching on the disease risk score in comparative effectiveness research of new treatments.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Comparative Effectiveness Research; Computer Simulation; Dabigatran; Female; Humans; Male; Mortality; Pharmacoepidemiology; Propensity Score; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Cardiology; Cost-Benefit Analysis; Cross-Sectional Studies; Dabigatran; Health Care Surveys; Hematology; Humans; Internal Medicine; Practice Patterns, Physicians'; Primary Health Care; Rhode Island; Rivaroxaban; Specialization; Venous Thromboembolism; Warfarin | 2015 |
National Trends in Ambulatory Oral Anticoagulant Use.
Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; United States; Venous Thromboembolism; Warfarin; Young Adult | 2015 |
Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Patient Admission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Europe; Female; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Middle Aged; Risk; Rivaroxaban; Thromboembolism; Thrombophilia; Vitamin K; Warfarin; Young Adult | 2015 |
Extreme warfarin hypersensitivity after oophorectomy.
Topics: Anticoagulants; Blood Coagulation Factors; Dabigatran; Drug Hypersensitivity; Drug Substitution; Female; Heparin; Humans; International Normalized Ratio; Middle Aged; Ovariectomy; Venous Thromboembolism; Vitamin K; Warfarin | 2015 |
Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Fibrinolytic Agents; Hemorrhage; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Self Care; Stroke; Thrombosis; Vitamin K; Warfarin | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function.
Topics: Animals; Anticoagulants; Antithrombins; Aorta; Bone and Bones; Bone Diseases, Metabolic; Bone Remodeling; Calcinosis; Dabigatran; Female; Fractures, Spontaneous; Iliac Artery; Kidney; Minerals; Osteoblasts; Osteoclasts; Random Allocation; Rats; Rats, Sprague-Dawley; Vascular Diseases; Vitamin K; Warfarin | 2015 |
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Hemorrhage; Humans; Kaplan-Meier Estimate; Models, Economic; Pulmonary Embolism; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Comparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anxiety; Atrial Fibrillation; Dabigatran; Depression; Female; Humans; Male; Prospective Studies; Quality of Life; Risk Factors; Warfarin | 2017 |
Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation.
Topics: Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; International Normalized Ratio; Kinetics; Prosthesis Design; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Effect of Renal Function on Anticoagulation Therapy in Asian Patients.
Topics: Creatinine; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Stroke; Warfarin | 2015 |
[General practice study confirms a favorable risk benefit profile].
Topics: Atrial Fibrillation; Dabigatran; Drug Approval; General Practice; Hemorrhage; Humans; Risk Assessment; Warfarin | 2015 |
Dabigatran use in elderly patients with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Drug Utilization Review; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Quebec; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2016 |
Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hospitalization; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Propensity Score; Retrospective Studies; United States; Warfarin | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Dabigatran; Dipyridamole; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Ticlopidine; Warfarin | 2015 |
What Do Anticoagulants Say about Microemboli?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Warfarin | 2015 |
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2015 |
Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Outcome Assessment, Health Care; Stroke; Warfarin | 2016 |
Clinical Features of Ischemic Stroke during Treatment with Dabigatran: An Association between Decreased Severity and a Favorable Prognosis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Discharge; Prognosis; Retrospective Studies; Risk Factors; Stroke; Warfarin | 2015 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Pulmonary Embolism; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thrombosis; Warfarin | 2015 |
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Disease-Free Survival; Drug Evaluation; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Insurance Coverage; Kaplan-Meier Estimate; Male; Middle Aged; Military Personnel; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Evaluation; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Insurance Coverage; Male; Middle Aged; Myocardial Infarction; Polypharmacy; Propensity Score; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Pradaxa-induced esophageal ulcer.
Topics: Aged; Anticoagulants; Dabigatran; Embolism; Endoscopy, Gastrointestinal; Esophageal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Stomach; Ulcer; Warfarin | 2015 |
Management of acute pulmonary embolism.
Topics: Acute Disease; Age Factors; Ambulatory Care; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Disease Management; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Male; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Vena Cava Filters; Warfarin | 2015 |
Dabigatran Use Does Not Increase Intracranial Hemorrhage in Traumatic Geriatric Falls When Compared with Warfarin.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; California; Dabigatran; Female; Follow-Up Studies; Glasgow Coma Scale; Humans; Incidence; Intracranial Hemorrhages; Male; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Thromboembolism; Warfarin; Wounds and Injuries | 2015 |
Direct oral anticoagulants and the bleeding patient.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Charcoal; Dabigatran; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Tranexamic Acid; Warfarin | 2016 |
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2015 |
Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Component Transfusion; Coronary Artery Bypass; Dabigatran; Drug Costs; Female; Humans; Length of Stay; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2015 |
[The Use of Dabigatran for Prevention of Thromboembolic Complications in Patients Underwent Atrial Fibrillation Catheter Ablation].
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Siberia; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Health Knowledge, Attitudes, Practice; Healthcare Disparities; Hemorrhage; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Quebec; Risk Assessment; Risk Factors; Sex Factors; Stroke; Treatment Outcome; Warfarin | 2015 |
Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Female; Follow-Up Studies; Hospital Administration; Humans; Incidence; Male; Registries; Risk; Thromboembolism; Time Factors; Warfarin | 2015 |
Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Databases, Factual; Female; Hospitalization; Humans; Length of Stay; Male; Medical Audit; Middle Aged; Patient Readmission; Propensity Score; Retrospective Studies; Time Factors; Warfarin | 2015 |
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Drug Costs; Female; Health Expenditures; Humans; Male; Retrospective Studies; United States; Warfarin | 2016 |
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2015 |
'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; New Zealand; Population Surveillance; Retrospective Studies; Risk Assessment; Survival Rate; Time Factors; Warfarin | 2016 |
Developing alerting thresholds for prospective drug safety monitoring.
Topics: Anticoagulants; Benchmarking; Clinical Trials as Topic; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Pharmacoepidemiology; Product Surveillance, Postmarketing; Risk; Warfarin | 2016 |
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Portugal; Pyrazoles; Pyridones; Stroke; Warfarin | 2015 |
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Canada; Dabigatran; Female; Guidelines as Topic; Humans; Internship and Residency; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Surveys and Questionnaires; Treatment Outcome; Universities; Warfarin | 2016 |
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2016 |
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Rivaroxaban; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Warfarin | 2016 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2015 |
Novel oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Family; Humans; Professional-Patient Relations; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Case-Control Studies; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Stroke; Taiwan; Warfarin | 2016 |
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Patient Compliance; Pyrazoles; Pyridones; Retrospective Studies; Stroke; Surveys and Questionnaires; Treatment Outcome; Warfarin | 2016 |
Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Costs; Emergency Service, Hospital; Female; Health Resources; Humans; Male; Middle Aged; Office Visits; Propensity Score; Retrospective Studies; United States; Warfarin | 2016 |
The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Choice Behavior; Dabigatran; Female; Humans; Male; Retrospective Studies; Social Class; Warfarin | 2016 |
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Perioperative Period; Surgical Procedures, Operative; Thromboembolism; Warfarin | 2016 |
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin | 2016 |
[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Costs; Humans; Morpholines; Portugal; Rivaroxaban; Stroke; Warfarin | 2016 |
[Anticoagulants after acute ischemic stroke with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Deglutition Disorders; Humans; Medical Records; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Time Factors; Time-to-Treatment; Treatment Outcome; Warfarin | 2016 |
A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS
Topics: Antithrombins; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Cost-Benefit Analysis; Dabigatran; Humans; Japan; Markov Chains; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Severity of Illness Index; Warfarin | 2017 |
Direct oral anticoagulant drugs (DOAC).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Loss, Surgical; Cataract Extraction; Dabigatran; Eye Hemorrhage; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Retrospective Studies; Warfarin | 2017 |
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Ontario; Renal Insufficiency, Chronic; Risk; Rivaroxaban; Warfarin | 2016 |
Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Expenditures; Humans; Insurance Benefits; Male; Medicare; Middle Aged; Rivaroxaban; Stroke; United States; Warfarin | 2016 |
Ask the doctor. My wife's medication to treat atrial fibrillation recently was changed from warfarin to a new drug called Pradaxa. They say that the new medicine does not require regular INR tests and is just as effective. Is that so?
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; International Normalized Ratio; Spouses; Warfarin | 2011 |
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Australia; Dabigatran; Drug Prescriptions; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2016 |
Which oral anticoagulant for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Patient Selection; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Management of bleeding complications in patients with cancer on DOACs.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2016 |
A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Registries; Stroke; Warfarin | 2016 |
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2016 |
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Anticoagulants: What is new and what is the standard?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Thromboembolism; United States; Warfarin | 2016 |
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dementia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Hematoma; Hospital Mortality; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Tomography, X-Ray Computed; Warfarin | 2016 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Israel; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2016 |
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Trees; Female; Humans; Male; Markov Chains; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Septal Occluder Device; Stroke; Survival Rate; Warfarin | 2016 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Propensity Score; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin; Withholding Treatment | 2016 |
Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Stroke; Warfarin | 2016 |
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticoagulants; Brain; Calcium-Binding Proteins; Dabigatran; Disease Models, Animal; Female; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Mutation; Neuroglia; Peptide Fragments; Presenilin-1; Warfarin | 2016 |
Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Female; Heart Atria; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Regression Analysis; Retrospective Studies; Risk Factors; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2017 |
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Stroke; Taiwan; Warfarin | 2017 |
Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Connecticut; Dabigatran; Demography; Factor Xa Inhibitors; Female; Humans; Injury Severity Score; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Trauma Centers; Warfarin; Wounds and Injuries | 2016 |
Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiac Surgical Procedures; Dabigatran; Emergencies; Female; Gastrointestinal Hemorrhage; Heart Transplantation; Hemorrhage; Hemostatics; Heparin; Humans; Incidence; International Normalized Ratio; Intracranial Hemorrhages; Laparotomy; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thrombocytopenia; Thromboembolism; Vitamin K; Warfarin | 2016 |
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; United States; Warfarin; Young Adult | 2016 |
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Warfarin | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diabetes Mellitus; Female; Guideline Adherence; Heart Failure; Humans; Hypertension; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk; Risk Assessment; Stroke; Ticlopidine; United States; United States Department of Veterans Affairs; Warfarin | 2016 |
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2016 |
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Norway; Prescription Drugs; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2017 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Internet; Patient Education as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2016 |
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Denmark; Female; Hospitalization; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Readmission; Percutaneous Coronary Intervention; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stents; Stroke; Thrombosis; Venous Thromboembolism; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Thrombophilia; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2016 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Rivaroxaban; Warfarin | 2017 |
Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hong Kong; Humans; Incidence; Male; Retrospective Studies; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Warfarin | 2017 |
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Bias; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Research Design; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Frequency and cost of acute surgical admissions in over-anticoagulated patients: over-anticoagulation in the community.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Erythrocyte Transfusion; Female; General Surgery; Hemostasis, Surgical; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Medical Overuse; Middle Aged; New Zealand; Warfarin | 2018 |
Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medicaid; Medicare; Treatment Outcome; United States; Warfarin | 2017 |
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin | 2016 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Rivaroxaban; Warfarin | 2017 |
Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Taiwan; Warfarin | 2017 |
Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.
Topics: Animals; Anticoagulants; Capillary Permeability; Dabigatran; Hemorrhage; Inflammation; Influenza A Virus, H1N1 Subtype; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Pulmonary Alveoli; Survival Analysis; Warfarin | 2016 |
Risk of intraocular hemorrhage with new oral anticoagulants.
Topics: Anticoagulants; Dabigatran; Eye Hemorrhage; Humans; Ocular Hypertension; Odds Ratio; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2017 |
Thromboelastogram does not detect pre-injury anticoagulation in acute trauma patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Case-Control Studies; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Retrospective Studies; Thrombelastography; Warfarin; Wounds, Nonpenetrating | 2017 |
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Child; Child, Preschool; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin; World Health Organization; Young Adult | 2017 |
Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Gastrointestinal Hemorrhage; Humans; Neoplasms; Stroke; Warfarin | 2017 |
Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hospital Costs; Humans; Male; Medicare; Patient Admission; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Hospital Mortality; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Recombinant Proteins; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Warfarin | 2017 |
Trends in oral anticoagulant use in Qatar: a 5-year experience.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Utilization Review; Female; Humans; Male; Prescriptions; Qatar; Rivaroxaban; Warfarin | 2017 |
The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Behavior; Humans; International Normalized Ratio; Male; Middle Aged; Models, Econometric; Patient Compliance; Patient Satisfaction; Rivaroxaban; Russia; Stroke; Warfarin | 2017 |
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Data Collection; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Observational Studies as Topic; Patient Selection; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke; Warfarin | 2017 |
Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2017 |
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER
Topics: Adult; Aged; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pulmonary Embolism; Stroke; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2017 |
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Erythrocyte Transfusion; Factor VIIa; Female; Hemorrhage; Hospital Mortality; Humans; Male; Medication Therapy Management; Ontario; Recombinant Proteins; Retrospective Studies; Stroke; Warfarin | 2017 |
A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Transfusion; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Incidence; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2017 |
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Blood Transfusion; Cohort Studies; Dabigatran; Endoscopic Mucosal Resection; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Rivaroxaban; Statistics, Nonparametric; Stomach Neoplasms; Thromboembolism; Treatment Outcome; Warfarin | 2017 |
Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Patient Education as Topic; Quality of Life; Warfarin | 2017 |
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.
Topics: Accidental Falls; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Poisson Distribution; Propensity Score; Retrospective Studies; Risk; Spinal Fractures; Stroke; Warfarin | 2017 |
Anticoagulation therapy: Uninterrupted dabigatran during ablation for AF.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation; Cerebral Hemorrhage; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Disability Evaluation; Factor Xa Inhibitors; Female; Hematoma; Humans; Japan; Linear Models; Male; Middle Aged; Multivariate Analysis; Patient Discharge; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Tomography, X-Ray Computed; Treatment Outcome; Warfarin | 2017 |
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Chi-Square Distribution; Comparative Effectiveness Research; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medicare Part D; Multivariate Analysis; Patient Admission; Propensity Score; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Treatment Outcome; United States; Warfarin | 2017 |
Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Comorbidity; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dabigatran; Female; Humans; Injury Severity Score; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Ticlopidine; Trauma Centers; Warfarin; Wounds and Injuries; Wounds, Nonpenetrating | 2017 |
Response by Bai et al to Letter Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Letter by Machado-Alba et al Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Warfarin | 2017 |
[Measurement of Prothrombin Fragment 1+2 for the Assessment of Anticoagulant Activity in Patients Treated with Warfarin or Non-vitamin K Antagonist Oral Anticoagulant].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Peptide Fragments; Prothrombin; Rivaroxaban; Warfarin | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Reply: Mortality and Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Topics: Acute Kidney Injury; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2017 |
Mortality and Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Topics: Acute Kidney Injury; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2017 |
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Expenditures; Health Resources; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Female; Health Care Costs; Hospitalization; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Propensity Score; Proportional Hazards Models; Quality of Life; Retrospective Studies; Risk; Stroke; Warfarin | 2017 |
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Hospitalization; Humans; Male; Patient Acceptance of Health Care; Patient Readmission; Retrospective Studies; Stroke; United States; Warfarin | 2019 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Thrombocytopenia induced by dabigatran: two case reports.
Topics: Aged; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Thrombocytopenia; Thromboembolism; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles; Warfarin | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Decision Making; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Norway; Pyrazoles; Pyridones; Rivaroxaban; Warfarin; Young Adult | 2017 |
Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Female; Hemorrhage; Hong Kong; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Patient Readmission; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Utilization; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System.
Topics: Administration, Oral; Aged; Anticoagulants; Area Under Curve; Atrial Fibrillation; Dabigatran; Female; Humans; Lab-On-A-Chip Devices; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2017 |
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Follow-Up Studies; Health Care Costs; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stroke; Warfarin | 2017 |
New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Diet; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Prescriptions; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2017 |
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Sex-Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Chi-Square Distribution; Dabigatran; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Medicare; Multivariate Analysis; Myocardial Infarction; Patient Admission; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Time Factors; Treatment Outcome; United States; Warfarin | 2017 |
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Pills Never Work in the Bottle.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2017 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Risk of Intraocular Bleeding and the New Anticoagulants: Not Such a Big Effect.
Topics: Anticoagulants; Dabigatran; Eye Hemorrhage; Humans; Warfarin | 2017 |
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?
Topics: Aspirin; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Rivaroxaban; Warfarin | 2017 |
Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Humans; Male; Off-Label Use; Stroke; Warfarin | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Propensity Score; Retrospective Studies; Stroke; Warfarin | 2017 |
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiovascular Diseases; Clinical Decision-Making; Dabigatran; Drug Monitoring; Drug Resistance; Factor Xa Inhibitors; Focus Groups; General Practitioners; Hemorrhage; Humans; Medical Staff, Hospital; Medication Adherence; Norway; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Qualitative Research; Risk; Rivaroxaban; Warfarin | 2018 |
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; International Normalized Ratio; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2017 |
Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2017 |
Authors Have Incorrectly Calculated Need for Renal Dose Adjustments for NOACs.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2017 |
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriovenous Malformations; Aspirin; Blood Transfusion; Case-Control Studies; Dabigatran; Diverticulum; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Hemorrhoids; Hospitalization; Humans; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Anticoagulants; Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2017 |
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Eye Hemorrhage; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism; Warfarin | 2018 |
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
Topics: Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Venous Thrombosis; Warfarin | 2018 |
Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dabigatran; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Chronic Disease; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Treatment Outcome; Ultrasonography; Venous Thrombosis; Warfarin | 2018 |
Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Middle Aged; Myocardial Infarction; Patient Acceptance of Health Care; Retrospective Studies; Stroke; United States; Warfarin | 2018 |
Effects of Direct Oral Anticoagulants at the Peak Phase, Trough Phase, and After Vascular Injury.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Punctures; Pyrazoles; Pyridones; Rivaroxaban; Vascular System Injuries; Warfarin | 2018 |
Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Patient Safety; Proportional Hazards Models; Risk; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Female; Humans; Malaysia; Male; Medical Audit; Retrospective Studies; Stroke; Warfarin | 2017 |
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke.
Topics: Aged; Anticoagulants; Brain Ischemia; Chagas Cardiomyopathy; Dabigatran; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Stroke; Warfarin | 2018 |
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Hemorrhage; Humans; Middle Aged; Neoplasms; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult | 2018 |
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Dabigatran; Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Survival Analysis; Venous Thrombosis; Warfarin | 2018 |
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Models, Biological; Primary Prevention; Recurrence; Secondary Prevention; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain Ischemia; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Models, Biological; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study.
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Female; Health Care Costs; Humans; Male; Patient Acceptance of Health Care; Secondary Prevention; Stroke; Taiwan; Warfarin | 2018 |
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
Topics: Administration, Oral; Angiodysplasia; Anticoagulants; Antithrombins; Atrial Fibrillation; Colon; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intestinal Mucosa; Odds Ratio; Randomized Controlled Trials as Topic; Rectum; Retrospective Studies; Risk Factors; Treatment Outcome; Warfarin | 2018 |
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Propensity Score; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Male; Medicare; Retrospective Studies; Rivaroxaban; Thromboembolism; Treatment Outcome; United States; Warfarin | 2018 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Frail Elderly; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Warfarin | 2018 |
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; United States; Warfarin | 2018 |
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Warfarin; Withholding Treatment; Young Adult | 2018 |
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Models, Statistical; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
[Tactics of Selection of Anticoagulant Therapy in Patients With Atrial Fibrillation and Ischemic Heart Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Myocardial Ischemia; Pyridones; Rivaroxaban; Stroke; Warfarin | 2018 |
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Databases, Factual; Drug Costs; Female; Humans; Male; Medicare; Medication Adherence; Proportional Hazards Models; Retrospective Studies; Stroke; United States; Warfarin | 2018 |
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Echocardiography; Fatal Outcome; Heart Diseases; Heart Failure; Humans; Male; Thrombosis; Ticlopidine; Warfarin | 2018 |
Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Humans; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrazoles; Pyridones; Republic of Korea; Rivaroxaban; Warfarin | 2018 |
NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Humans; Incidence; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thrombolytic Therapy; Treatment Outcome; Victoria; Warfarin | 2019 |
Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Quebec; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2018 |
Direct oral anticoagulants for postoperative myocardial injury.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Warfarin | 2018 |
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.
Topics: Anticoagulants; Computer Simulation; Confounding Factors, Epidemiologic; Dabigatran; Data Interpretation, Statistical; Epidemiologic Research Design; Hemorrhage; Humans; Propensity Score; Risk Assessment; Stroke; Warfarin | 2018 |
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2018 |
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Safety; Primary Health Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2018 |
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Clinical Trials as Topic; Contraceptives, Oral, Hormonal; Dabigatran; Factor Xa Inhibitors; Female; Humans; Incidence; Menorrhagia; Middle Aged; Multicenter Studies as Topic; Uterine Hemorrhage; Venous Thromboembolism; Vitamin K; Warfarin; Young Adult | 2018 |
Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Humans; Male; National Health Programs; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Response to comments of manuscript: Increased risk of myocardial infarction with dabigatran etexilate: Fact or fiction? A critical meta-analysis from integrating randomized controlled trials and real-world studies: Wine or spritzer?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Warfarin; Wine | 2018 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bleeding Time; Blood Loss, Surgical; Dabigatran; Female; Humans; Male; Middle Aged; Prospective Studies; Reference Values; Risk Factors; Statistics, Nonparametric; Time Factors; Tooth Extraction; Treatment Outcome; Warfarin | 2018 |
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Obesity, Morbid; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2019 |
Anticoagulant-associated adverse drug reactions in 2013-15.
Topics: Age Distribution; Anticoagulants; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Distribution; Time Factors; Warfarin | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Decision-Making; Dabigatran; Databases, Factual; Enoxaparin; Female; Fondaparinux; Humans; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2018 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
Increased risk of myocardial infarction with dabigatran etexilate: Fact or fiction? A critical meta-analysis from integrating randomized controlled trials and real-world studies: Wine or spritzer?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin; Wine | 2018 |
Patient-Reported Treatment Satisfaction with Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation in China.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; China; Costs and Cost Analysis; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Self Report; Surveys and Questionnaires; Warfarin | 2018 |
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Humans; Male; Medicare; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2019 |
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Epistaxis; Female; Follow-Up Studies; Germany; Hospitalization; Humans; Length of Stay; Male; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Dabigatran - the First Approved DTI for SPAF.
Topics: Adenosine Triphosphatases; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Europe; Humans; India; Pyridines; Stroke; Warfarin | 2018 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
[Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2018 |
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2018 |
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hip Fractures; Humans; Male; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2019 |
Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Risk; Treatment Adherence and Compliance; United States; Warfarin | 2018 |
Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Progression; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Korea; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2018 |
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Embolism; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2019 |
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Adherence and Compliance; United States; Warfarin | 2019 |
The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; International Normalized Ratio; Logistic Models; Male; Multivariate Analysis; Practice Guidelines as Topic; Rivaroxaban; Stroke; Time Factors; Warfarin | 2019 |
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Factor Xa Inhibitors; Humans; Safety-Based Drug Withdrawals; Stroke; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2018 |
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
[Efficacy of Idarucizmab in Patients with Intracranial Hemorrhage Preconditioned with Dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Dabigatran; Humans; Intracranial Hemorrhages; Stroke; Warfarin | 2018 |
Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2019 |
Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Middle Aged; Odds Ratio; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin; Young Adult | 2019 |
Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Female; Humans; Male; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2018 |
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States; Warfarin; Young Adult | 2019 |
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Brazil; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Network meta-analysis: a new analysis tool of the experimental evidence.
Topics: Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Dabigatran; Dasatinib; Data Interpretation, Statistical; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Warfarin | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies.
Topics: Cohort Studies; Dabigatran; Data Interpretation, Statistical; Databases, Factual; Myocardial Infarction; Pharmacoepidemiology; Product Surveillance, Postmarketing; Propensity Score; Reproducibility of Results; United States; United States Food and Drug Administration; Warfarin | 2019 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2019 |
Cerebral Ischemia in Patients on Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Registries; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2019 |
New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antiphospholipid Syndrome; Antithrombins; Carotid Arteries; Computed Tomography Angiography; Dabigatran; Female; Follow-Up Studies; Humans; Product Surveillance, Postmarketing; Pulmonary Embolism; Stroke; Treatment Outcome; Venous Thrombosis; Warfarin | 2019 |
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Failure; Humans; Incidence; Kaplan-Meier Estimate; Male; Medicare; Patient Safety; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2019 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Secondary Bleeding During Acute Experimental Intracerebral Hemorrhage.
Topics: Acute Disease; Animals; Anticoagulants; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Male; Mice; Random Allocation; Warfarin | 2019 |
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Middle Aged; Pharmaceutical Preparations; Prospective Studies; Republic of Korea; Stroke; Warfarin | 2020 |
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Decision Making, Shared; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2019 |
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Australia; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Myocardial Infarction; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Veterans; Warfarin | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; United States Department of Defense; Warfarin; Young Adult | 2019 |
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Republic of Korea; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Can't get out of this world alive.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hospitalization; Humans; Warfarin | 2019 |
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke; Warfarin; Young Adult | 2019 |
Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes.
Topics: Administration, Oral; Algorithms; Anticoagulants; Asymptomatic Infections; Atrial Fibrillation; Computer Simulation; Dabigatran; Hemorrhage; Humans; Likelihood Functions; Meta-Analysis as Topic; Motivation; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2020 |
Anticoagulation and cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Phacoemulsification; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Thromboembolism; Warfarin | 2019 |
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Denmark; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Pyrazoles; Pyridones; Rivaroxaban; United States; Vitamin K; Warfarin | 2019 |
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
Topics: Aged; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Epistaxis; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Telangiectasia, Hereditary Hemorrhagic; Venous Thromboembolism; Warfarin | 2019 |
Outcome of Anticoagulation Therapy of Left Atrial Thrombus or Sludge in Patients With Nonvalvular Atrial Fibrillation or Flutter.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Echocardiography, Transesophageal; Female; Heart Atria; Humans; Male; Middle Aged; Rivaroxaban; Thrombosis; Treatment Outcome; Warfarin | 2019 |
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; France; Hemorrhage; Humans; Myocardial Infarction; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2020 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Percutaneous Coronary Intervention; Warfarin | 2019 |
Hematoma Risk After Needle Electromyography in Patients Using Newer Oral Anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Electromyography; Female; Hematoma; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2021 |
Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Defibrillators, Implantable; Female; Humans; Male; Middle Aged; Pyridones; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Pharmacogenomics of anticoagulation therapy: the last 10 years.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Dabigatran; Humans; Pharmacogenetics; Warfarin | 2019 |
Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Female; Fractures, Bone; Hip Fractures; Hospitalization; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Protective Factors; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2020 |
Atrial Fibrillation, Diabetes, and Percutaneous Coronary Intervention: A Complicated Triad.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Treatment Outcome; Warfarin | 2019 |
Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Taiwan; Warfarin | 2020 |
[How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2019 |
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin; Young Adult | 2020 |
Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Osteoporosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Warfarin | 2020 |
[Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cause of Death; Comorbidity; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2020 |
Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2020 |
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants.
Topics: Aged; Aged, 80 and over; Dabigatran; Emergency Service, Hospital; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Registries; Warfarin | 2020 |
Pulmonary Embolism in a Collegiate Softball Athlete: A Case Report.
Topics: Anticoagulants; Antithrombins; Athletes; Baseball; Chest Pain; Computed Tomography Angiography; Dabigatran; Dyspnea; Female; Hemoptysis; Humans; Pulmonary Embolism; Warfarin; Young Adult | 2020 |
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Treatment Outcome; Warfarin | 2020 |
Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Treatment Outcome; Warfarin | 2020 |
Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Ambulatory Care Facilities; Anticoagulants; China; Cities; Dabigatran; Drug Prescriptions; Female; Health Expenditures; Humans; Male; Middle Aged; Rivaroxaban; Warfarin; Young Adult | 2020 |
Trends in anticoagulant prescribing: a review of local policies in English primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
Health-related quality of life in patients receiving oral anti-coagulants: a cross-sectional study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; International Normalized Ratio; Male; Medication Adherence; Middle Aged; Quality of Life; Warfarin | 2020 |
Pulmonary vein thrombosis in a patient undergoing anticoagulation treatment: an intriguing clinical diagnosis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Drug Substitution; Female; Humans; Middle Aged; Pulmonary Veins; Pulmonary Veno-Occlusive Disease; Treatment Outcome; Vascular System Injuries; Venous Thrombosis; Warfarin | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2020 |
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Dabigatran; Humans; Risk Factors; Stroke; Thrombin; Warfarin | 2020 |
Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2020 |
Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Pyrazoles; Pyridones; Rivaroxaban; Spinal Fractures; Stroke; Warfarin | 2020 |
Mechanical Heart Valves Require Warfarin: No News Is Good News?
Topics: Anticoagulants; Dabigatran; Family Characteristics; Heart Valve Prosthesis; Heart Valves; Humans; Rivaroxaban; Thrombin; Warfarin | 2020 |
Blood pressure targets in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Dabigatran; Humans; Thrombin; Warfarin | 2020 |
Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Cohort Studies; Dabigatran; Databases, Factual; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Risk; Rivaroxaban; Warfarin | 2020 |
Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study.
Topics: Administration, Oral; Bacteremia; Cohort Studies; Dabigatran; Humans; Staphylococcus aureus; Stroke; Warfarin | 2021 |
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Warfarin | 2020 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Topics: Administration, Oral; Aged; Anticoagulants; Bioprosthesis; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2020 |
Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Health Services for the Aged; Humans; Male; Medicare; Risk Factors; Stroke; United States; Warfarin | 2020 |
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Endoscopic Mucosal Resection; Female; Humans; Japan; Male; Middle Aged; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stomach; Stomach Neoplasms; Thiazoles; Thromboembolism; Warfarin | 2021 |
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antithrombins; Chronic Disease; Dabigatran; Disease Progression; Drug Substitution; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Treatment Outcome; Warfarin | 2020 |
Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Medicare; Mortality; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; United States; Warfarin | 2020 |
Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Blood Coagulation; Comorbidity; Dabigatran; Female; Global Health; Humans; Kidney Function Tests; Male; Practice Patterns, Physicians'; Renal Insufficiency; Risk Adjustment; Severity of Illness Index; Venous Thromboembolism; Warfarin | 2021 |
Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis.
Topics: Adult; Anticoagulants; Antithrombins; Arteriovenous Fistula; Central Nervous System Vascular Malformations; Cerebral Angiography; Cerebral Veins; Cranial Sinuses; Dabigatran; Female; Humans; Imaging, Three-Dimensional; Intracranial Thrombosis; Magnetic Resonance Angiography; Male; Meningeal Arteries; Middle Aged; Randomized Controlled Trials as Topic; Secondary Prevention; Sinus Thrombosis, Intracranial; Venous Thrombosis; Warfarin | 2020 |
Dabigatran trough concentrations in very elderly patients.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Humans; Risk Factors; Warfarin | 2021 |
Postpolypectomy bleeding of colorectal polyps in patients with continuous warfarin and short-term interruption of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Colonic Polyps; Dabigatran; Hemorrhage; Humans; Male; Pyridones; Rivaroxaban; Warfarin | 2021 |
Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity.
Topics: Adult; Anticoagulants; Antithrombins; Dabigatran; Drug Substitution; Genetic Predisposition to Disease; Hemostasis; Heparin; Homozygote; Humans; Male; Myocardial Infarction; Phenotype; Plasminogen Activator Inhibitor 1; Sinus Thrombosis, Intracranial; Time Factors; Treatment Failure; Warfarin | 2020 |
Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Warfarin; Young Adult | 2020 |
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2021 |
Atrial fibrillation, an equivalent of cardiovascular disease risk.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Dabigatran; Humans; Thrombin; Warfarin | 2020 |
Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Dabigatran; Humans; Patient Selection; Thrombin; Warfarin | 2020 |
Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Thrombosis; Warfarin | 2021 |
Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Female; General Practice; Geography; Humans; Logistic Models; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Warfarin | 2021 |
Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Warfarin | 2022 |
Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Czech Republic; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Retrospective Studies; Stroke; Warfarin | 2021 |
Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2021 |
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin | 2021 |
A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Singapore; Stroke; Vitamin K; Warfarin; Young Adult | 2020 |
Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Mortality; Propensity Score; Pyrazoles; Pyridones; Stroke; Warfarin | 2021 |
Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China.
Topics: Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Humans; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2021 |
Anticoagulant-related intracranial haemorrhage: time to anticoagulant reversal improving but still slower than thrombolysis for ischaemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; New Zealand; Retrospective Studies; Thrombolytic Therapy; Time Factors; Treatment Outcome; Warfarin | 2021 |
Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis.
Topics: Aged; Anticoagulants; Blood Transfusion; Cohort Studies; Colonic Polyps; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hong Kong; Humans; Male; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Rivaroxaban; Thromboembolism; Warfarin | 2022 |
Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Warfarin | 2021 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.
Topics: Animals; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Female; Humans; Mice; Vitamin K; Warfarin | 2021 |
Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Rivaroxaban; Stroke; Upper Gastrointestinal Tract; Warfarin | 2022 |
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin | 2021 |
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug.
Topics: Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Drug Therapy, Combination; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Recurrence; Warfarin | 2021 |
Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Diabetes Mellitus; Factor Xa Inhibitors; Female; Hong Kong; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Time Factors; Treatment Outcome; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin | 2021 |
Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Patient Satisfaction; Stroke; Surveys and Questionnaires; Taiwan; Warfarin | 2021 |
[Efficiency of the Decision-Making Module in the Personalized Choice of an Anticoagulant].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Middle Aged; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2021 |
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
RHEDAR study: Determination of the risk of gastrointestinal hemorrhage in treatment with dabigatran, acenocoumarol and rivaroxaban.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Warfarin | 2021 |
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Uterine Hemorrhage; Warfarin | 2021 |
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic the
Topics: Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Warfarin | 2021 |
Could DOAC Be a Better Choice Than Warfarin in Low Compliance Patients with Fontan Procedure?
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Fontan Procedure; Humans; Male; Retrospective Studies; Warfarin; Young Adult | 2021 |
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Ischemic Stroke; Male; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Risk; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2021 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus, Type 2; Electronic Health Records; Eye Diseases; Humans; Kidney; Kidney Diseases; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Ex Vivo Assessment of Different Oral Anticoagulant Regimens on Pump Thrombosis in a HeartWare Ventricular Assist Device.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Heart Failure; Heart-Assist Devices; Hemolysis; Humans; Platelet Aggregation Inhibitors; Thrombosis; Warfarin | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Warfarin | 2022 |
Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Frail Elderly; Humans; Male; Massachusetts; Medicare; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2021 |
Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin.
Topics: Administration, Oral; Anticoagulants; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2022 |
Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2021 |
The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Ontario; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Warfarin | 2021 |
Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study.
Topics: Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin | 2022 |
Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Humans; Obesity, Morbid; Retrospective Studies; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2022 |
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; Humans; Rivaroxaban; Stroke; Trust; Warfarin | 2022 |
Extensive skin necrosis in an elderly woman on dabigatran.
Topics: Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Necrosis; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Warfarin | 2021 |
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Humans; Kidney; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device.
Topics: Administration, Oral; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke; Thrombosis; Treatment Outcome; Warfarin | 2022 |
Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amyloidosis; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiomyopathies; Dabigatran; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Heparin; Humans; Kinetics; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2022 |
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Embolism; Hemorrhage; Humans; Risk Factors; Stroke; Warfarin | 2022 |
Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Female; Humans; Male; Propensity Score; Scotland; Stroke; Warfarin | 2022 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |
Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Cohort Studies; Dabigatran; General Practice; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Acute elevation of liver function test values following concomitant administration of dabigatran and primidone.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; International Normalized Ratio; Liver Function Tests; Male; Primidone; Warfarin | 2022 |
Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug-Related Side Effects and Adverse Reactions; Humans; Intracranial Hemorrhages; Pyridones; Rivaroxaban; Warfarin | 2022 |
Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Mitral Valve Stenosis; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Frequency of hemorrhage after tooth extraction in patients treated with a direct oral anticoagulant: A multicenter cross-sectional study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Male; Prospective Studies; Pyridones; Rivaroxaban; Tooth Extraction; Warfarin | 2022 |
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Epistaxis; Humans; Propensity Score; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; England; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Interrupted Time Series Analysis; Pandemics; Prescriptions; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Stroke; Warfarin | 2022 |
The changing use of anticoagulants in New Zealand.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; New Zealand; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Overweight; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vasculitis; Warfarin | 2022 |
Warfarin Is Associated With Higher Rates of Upper But Not Lower Gastrointestinal Bleeding Compared with Direct Oral Anticoagulants: A Population-Based Propensity-Weighted Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Stroke; Warfarin | 2023 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Understanding variation in the results of real-world evidence studies that seem to address the same question.
Topics: Dabigatran; Hemorrhage; Humans; Warfarin | 2022 |
[Mitral Mechanical Valve Thrombosis after Switching to Dabigatran].
Topics: Aged; Anticoagulants; Dabigatran; Heart Valve Prosthesis; Humans; Male; Mitral Valve; Thrombosis; Warfarin | 2022 |
Bleeding risk of oral anticoagulants in liver cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Liver Cirrhosis; New Zealand; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2022 |
Reply to the Comment on "Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Warfarin | 2022 |
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2022 |
Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Cross-Sectional Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicaid; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Lung Diseases, Interstitial; Male; Retrospective Studies; Taiwan; Warfarin | 2022 |
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin | 2023 |
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparison of medication adherence to different oral anticoagulants: population-based cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Medication Adherence; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Adolescent; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Female; Humans; Male; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Direct oral anticoagulants and warfarin safety in rural patients with obesity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Retrospective Studies; Rural Population; Stroke; Warfarin | 2023 |
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Developing Countries; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Dementia; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Kidney; Rivaroxaban; Stroke; Warfarin | 2023 |
Cost-Effectiveness of Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Hong Kong.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hong Kong; Humans; Rivaroxaban; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Hypertension; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Kidney Transplantation; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medication Adherence; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Utilization outcomes of direct oral anticoagulants in Medicare patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicare; Retrospective Studies; Rivaroxaban; United States; Venous Thromboembolism; Warfarin | 2023 |
Pearls in Anticoagulation Management for Patients With Left Ventricular Assist Devices.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Heart-Assist Devices; Humans; Pyridones; Stroke; Warfarin | 2023 |
Safety and efficacy of oral anticoagulants in extreme weights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Thinness; Venous Thromboembolism; Warfarin | 2023 |
Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Stroke; Subarachnoid Hemorrhage; Vitamin K; Warfarin | 2023 |